0220.50P3Yfalse--12-31FY2019000002166582000000760000001.591.661.71112000000000200000000014657063601465706360P364DP15YP7YP20YP2Y0000750000007500000075000000750000001050000005P3Y
0000021665
2019-01-01
2019-12-31
0000021665
cl:A1.375NotesDue2034Member
2019-01-01
2019-12-31
0000021665
us-gaap:CommonStockMember
2019-01-01
2019-12-31
0000021665
cl:A0.500NotesDue2026Member
2019-01-01
2019-12-31
0000021665
cl:A0.000Notesdue2021Member
2019-01-01
2019-12-31
0000021665
cl:A0.875Notesdue2039Member
2019-01-01
2019-12-31
0000021665
2019-06-30
0000021665
2020-01-31
0000021665
us-gaap:OneTimeTerminationBenefitsMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
cl:IncrementalDepreciationAndAssetImpairmentMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
cl:ChargesResultingDirectlyFromExitActivitiesMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
cl:ImplementationOfNewStrategiesMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
2018-01-01
2018-12-31
0000021665
2017-01-01
2017-12-31
0000021665
2018-12-31
0000021665
2019-12-31
0000021665
us-gaap:NoncontrollingInterestMember
2016-12-31
0000021665
us-gaap:NoncontrollingInterestMember
2019-01-01
2019-12-31
0000021665
us-gaap:CommonStockMember
2017-12-31
0000021665
cl:UnearnedCompensationMember
2016-12-31
0000021665
cl:UnearnedCompensationMember
2019-12-31
0000021665
us-gaap:NoncontrollingInterestMember
2018-01-01
2018-12-31
0000021665
us-gaap:AdditionalPaidInCapitalMember
2019-01-01
2019-12-31
0000021665
us-gaap:AdditionalPaidInCapitalMember
2018-01-01
2018-12-31
0000021665
us-gaap:RetainedEarningsMember
2017-12-31
0000021665
us-gaap:TreasuryStockMember
2019-01-01
2019-12-31
0000021665
cl:UnearnedCompensationMember
2017-01-01
2017-12-31
0000021665
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2016-12-31
0000021665
us-gaap:RetainedEarningsMember
2019-12-31
0000021665
us-gaap:RetainedEarningsMember
2017-01-01
2017-12-31
0000021665
us-gaap:TreasuryStockMember
2018-12-31
0000021665
us-gaap:NoncontrollingInterestMember
2017-12-31
0000021665
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2017-12-31
0000021665
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-12-31
0000021665
cl:UnearnedCompensationMember
2018-01-01
2018-12-31
0000021665
us-gaap:TreasuryStockMember
2016-12-31
0000021665
us-gaap:RetainedEarningsMember
2019-01-01
2019-12-31
0000021665
us-gaap:RetainedEarningsMember
2018-01-01
2018-12-31
0000021665
us-gaap:AdditionalPaidInCapitalMember
2017-01-01
2017-12-31
0000021665
us-gaap:AdditionalPaidInCapitalMember
2017-12-31
0000021665
cl:UnearnedCompensationMember
2019-01-01
2019-12-31
0000021665
us-gaap:RetainedEarningsMember
2016-12-31
0000021665
us-gaap:TreasuryStockMember
2018-01-01
2018-12-31
0000021665
us-gaap:NoncontrollingInterestMember
2017-01-01
2017-12-31
0000021665
us-gaap:AdditionalPaidInCapitalMember
2016-12-31
0000021665
us-gaap:TreasuryStockMember
2017-01-01
2017-12-31
0000021665
us-gaap:RetainedEarningsMember
2018-12-31
0000021665
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-01-01
2018-12-31
0000021665
us-gaap:CommonStockMember
2019-12-31
0000021665
us-gaap:AdditionalPaidInCapitalMember
2019-12-31
0000021665
us-gaap:TreasuryStockMember
2017-12-31
0000021665
us-gaap:NoncontrollingInterestMember
2018-12-31
0000021665
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-12-31
0000021665
us-gaap:CommonStockMember
2018-12-31
0000021665
cl:UnearnedCompensationMember
2017-12-31
0000021665
us-gaap:AdditionalPaidInCapitalMember
2018-12-31
0000021665
us-gaap:TreasuryStockMember
2019-12-31
0000021665
cl:UnearnedCompensationMember
2018-12-31
0000021665
us-gaap:NoncontrollingInterestMember
2019-12-31
0000021665
us-gaap:CommonStockMember
2016-12-31
0000021665
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-01-01
2019-12-31
0000021665
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2017-01-01
2017-12-31
0000021665
2019-01-01
2019-03-31
0000021665
2018-01-01
2018-03-31
0000021665
2017-01-01
2017-03-31
0000021665
2017-12-31
0000021665
2016-12-31
0000021665
cl:PersonalCareMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2018-01-01
2018-12-31
0000021665
cl:PersonalCareMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2017-01-01
2017-12-31
0000021665
cl:OralCareMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2017-01-01
2017-12-31
0000021665
cl:PetNutritionMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2017-01-01
2017-12-31
0000021665
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2019-01-01
2019-12-31
0000021665
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2017-01-01
2017-12-31
0000021665
cl:PetNutritionMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2018-01-01
2018-12-31
0000021665
cl:PersonalCareMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2019-01-01
2019-12-31
0000021665
cl:HomeCareMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2018-01-01
2018-12-31
0000021665
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2018-01-01
2018-12-31
0000021665
cl:OralCareMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2018-01-01
2018-12-31
0000021665
cl:PetNutritionMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2019-01-01
2019-12-31
0000021665
cl:HomeCareMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2017-01-01
2017-12-31
0000021665
cl:OralCareMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2019-01-01
2019-12-31
0000021665
cl:HomeCareMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2019-01-01
2019-12-31
0000021665
us-gaap:AccountingStandardsUpdate201802Member
2018-01-01
2018-03-31
0000021665
us-gaap:AccountingStandardsUpdate201602Member
2019-01-01
0000021665
us-gaap:ShippingAndHandlingMember
2018-01-01
2018-12-31
0000021665
srt:MaximumMember
cl:LocalBrandsTrademarksCustomerRelationshipsAndNonCompeteAgreementsMember
2019-01-01
2019-12-31
0000021665
us-gaap:ShippingAndHandlingMember
2017-01-01
2017-12-31
0000021665
us-gaap:ShippingAndHandlingMember
2019-01-01
2019-12-31
0000021665
srt:MinimumMember
cl:LocalBrandsTrademarksCustomerRelationshipsAndNonCompeteAgreementsMember
2019-01-01
2019-12-31
0000021665
srt:MinimumMember
us-gaap:MachineryAndEquipmentMember
2019-01-01
2019-12-31
0000021665
srt:MaximumMember
us-gaap:MachineryAndEquipmentMember
2019-01-01
2019-12-31
0000021665
srt:MaximumMember
us-gaap:BuildingMember
2019-01-01
2019-12-31
0000021665
cl:PhysiciansCareAllianceLLCAndEltaMDHoldingsInc.Member
2018-01-31
0000021665
cl:LaboratoiresFilorgaCosmtiquesMember
us-gaap:CustomerRelationshipsMember
2019-09-19
2019-09-19
0000021665
cl:LaboratoiresFilorgaCosmtiquesMember
2019-09-19
2019-09-19
0000021665
cl:PhysiciansCareAllianceLLCAndEltaMDHoldingsInc.Member
us-gaap:CustomerRelationshipsMember
2018-01-31
0000021665
cl:PhysiciansCareAllianceLLCAndEltaMDHoldingsInc.Member
2018-01-01
2018-01-31
0000021665
cl:PhysiciansCareAllianceLLCAndEltaMDHoldingsInc.Member
us-gaap:TrademarksMember
2018-01-31
0000021665
srt:MinimumMember
cl:PhysiciansCareAllianceLLCAndEltaMDHoldingsInc.Member
us-gaap:CustomerRelationshipsMember
2018-01-01
2018-01-31
0000021665
cl:NigeriaJointVentureMember
2019-08-15
0000021665
cl:LaboratoiresFilorgaCosmtiquesMember
2019-10-01
2019-12-31
0000021665
cl:HelloProductLLCMember
us-gaap:SubsequentEventMember
2020-01-31
2020-01-31
0000021665
srt:EuropeMember
cl:LaboratoiresFilorgaCosmtiquesMember
cl:OralPersonalAndHomeCareMember
2019-09-19
0000021665
cl:PhysiciansCareAllianceLLCAndEltaMDHoldingsInc.Member
us-gaap:TrademarksMember
2018-01-01
2018-01-31
0000021665
cl:PhysiciansCareAllianceLLCAndEltaMDHoldingsInc.Member
srt:NorthAmericaMember
2018-01-31
0000021665
srt:MaximumMember
cl:PhysiciansCareAllianceLLCAndEltaMDHoldingsInc.Member
us-gaap:CustomerRelationshipsMember
2018-01-01
2018-01-31
0000021665
cl:LaboratoiresFilorgaCosmtiquesMember
us-gaap:TrademarksMember
2019-09-19
0000021665
cl:LaboratoiresFilorgaCosmtiquesMember
us-gaap:CustomerRelationshipsMember
2019-09-19
0000021665
cl:NigeriaJointVentureMember
2019-08-15
2019-08-15
0000021665
cl:LaboratoiresFilorgaCosmtiquesMember
2019-09-19
0000021665
2019-10-01
2019-12-31
0000021665
cl:ThirdPartyIncrementalCostMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
us-gaap:OneTimeTerminationBenefitsMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
us-gaap:CorporateNonSegmentMember
2019-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
cl:ExpectedCompletionDate2019Member
srt:MinimumMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
cl:ThirdPartyIncrementalCostMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
us-gaap:OneTimeTerminationBenefitsMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
us-gaap:ContractTerminationMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
us-gaap:ContractTerminationMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
us-gaap:OneTimeTerminationBenefitsMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
cl:ThirdPartyIncrementalCostMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
srt:NorthAmericaMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
cl:PetNutritionMember
2019-12-31
0000021665
us-gaap:LandAndBuildingMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
cl:AfricaEurasiaMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
srt:EuropeMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
srt:AsiaMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
us-gaap:ContractTerminationMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
srt:LatinAmericaMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
cl:OtherIncomeExpenseNetMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
us-gaap:SellingGeneralAndAdministrativeExpensesMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
cl:OtherIncomeExpenseNetMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
cl:NonServiceRelatedPostretirementCostsMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
us-gaap:SellingGeneralAndAdministrativeExpensesMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
us-gaap:SellingGeneralAndAdministrativeExpensesMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
cl:NonServiceRelatedPostretirementCostsMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
cl:OtherIncomeExpenseNetMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
cl:GrossProfitMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
cl:GrossProfitMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
cl:NonServiceRelatedPostretirementCostsMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
cl:GrossProfitMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
srt:EuropeMember
cl:GlobalGrowthandEfficiencyProgramMember
2012-10-01
2018-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
us-gaap:CorporateNonSegmentMember
2012-10-01
2018-12-31
0000021665
srt:NorthAmericaMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
srt:LatinAmericaMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
cl:AfricaEurasiaMember
cl:GlobalGrowthandEfficiencyProgramMember
2012-10-01
2018-12-31
0000021665
cl:AfricaEurasiaMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
cl:PetNutritionMember
2019-01-01
2019-12-31
0000021665
cl:AfricaEurasiaMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
cl:PetNutritionMember
2018-01-01
2018-12-31
0000021665
cl:AfricaEurasiaMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
srt:AsiaMember
cl:GlobalGrowthandEfficiencyProgramMember
2012-10-01
2018-12-31
0000021665
srt:EuropeMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
srt:EuropeMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
cl:PetNutritionMember
2017-01-01
2017-12-31
0000021665
srt:AsiaMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
srt:LatinAmericaMember
cl:GlobalGrowthandEfficiencyProgramMember
2012-10-01
2018-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2012-10-01
2018-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
us-gaap:CorporateNonSegmentMember
2019-01-01
2019-12-31
0000021665
srt:AsiaMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
cl:PetNutritionMember
2012-10-01
2018-12-31
0000021665
srt:NorthAmericaMember
cl:GlobalGrowthandEfficiencyProgramMember
2012-10-01
2018-12-31
0000021665
srt:AsiaMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
srt:NorthAmericaMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
srt:NorthAmericaMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
us-gaap:CorporateNonSegmentMember
2017-01-01
2017-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
us-gaap:CorporateNonSegmentMember
2018-01-01
2018-12-31
0000021665
srt:LatinAmericaMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
srt:EuropeMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
srt:LatinAmericaMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
cl:AssetImpairmentMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
cl:IncrementalDepreciationMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
us-gaap:OtherRestructuringMember
cl:GlobalGrowthandEfficiencyProgramMember
2016-12-31
0000021665
us-gaap:OtherRestructuringMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
cl:AssetImpairmentMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
us-gaap:OtherRestructuringMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-12-31
0000021665
cl:IncrementalDepreciationMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
us-gaap:OtherRestructuringMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
cl:AssetImpairmentMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
cl:IncrementalDepreciationMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2018-12-31
0000021665
cl:IncrementalDepreciationMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-12-31
0000021665
us-gaap:OneTimeTerminationBenefitsMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-12-31
0000021665
cl:AssetImpairmentMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2016-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2017-12-31
0000021665
us-gaap:OtherRestructuringMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
cl:AssetImpairmentMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-12-31
0000021665
us-gaap:OtherRestructuringMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
us-gaap:OtherRestructuringMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-12-31
0000021665
cl:IncrementalDepreciationMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-12-31
0000021665
cl:IncrementalDepreciationMember
cl:GlobalGrowthandEfficiencyProgramMember
2016-12-31
0000021665
us-gaap:OneTimeTerminationBenefitsMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-12-31
0000021665
cl:IncrementalDepreciationMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-12-31
0000021665
us-gaap:OneTimeTerminationBenefitsMember
cl:GlobalGrowthandEfficiencyProgramMember
2016-12-31
0000021665
cl:AssetImpairmentMember
cl:GlobalGrowthandEfficiencyProgramMember
2016-12-31
0000021665
cl:AssetImpairmentMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-12-31
0000021665
us-gaap:OtherIntangibleAssetsMember
2019-12-31
0000021665
us-gaap:TrademarksMember
2018-12-31
0000021665
us-gaap:TrademarksMember
2019-12-31
0000021665
us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember
2018-12-31
0000021665
us-gaap:OtherIntangibleAssetsMember
2018-12-31
0000021665
us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember
2019-12-31
0000021665
srt:AsiaPacificMember
cl:OralPersonalAndHomeCareMember
2019-12-31
0000021665
srt:LatinAmericaMember
cl:OralPersonalAndHomeCareMember
2019-12-31
0000021665
cl:AfricaEurasiaMember
cl:OralPersonalAndHomeCareMember
2019-12-31
0000021665
cl:PetNutritionMember
2018-12-31
0000021665
srt:LatinAmericaMember
cl:OralPersonalAndHomeCareMember
2018-12-31
0000021665
srt:NorthAmericaMember
cl:OralPersonalAndHomeCareMember
2019-12-31
0000021665
cl:AfricaEurasiaMember
cl:OralPersonalAndHomeCareMember
2018-12-31
0000021665
srt:AsiaPacificMember
cl:OralPersonalAndHomeCareMember
2018-12-31
0000021665
srt:NorthAmericaMember
cl:OralPersonalAndHomeCareMember
2018-12-31
0000021665
cl:OralPersonalAndHomeCareMember
2019-12-31
0000021665
srt:EuropeMember
cl:OralPersonalAndHomeCareMember
2019-12-31
0000021665
cl:PetNutritionMember
2019-12-31
0000021665
srt:EuropeMember
cl:OralPersonalAndHomeCareMember
2018-12-31
0000021665
cl:OralPersonalAndHomeCareMember
2018-12-31
0000021665
cl:A1.75percentMember
2019-12-31
0000021665
cl:Twentyyearnotesat0.875percentMember
2019-12-31
0000021665
cl:Fifteenyearnotesat1.375percentMember
2019-03-31
0000021665
cl:AmendedDomesticRevolvingCreditFacility2650MillionCapacityMember
2019-08-01
2019-08-31
0000021665
cl:AmendedDomesticRevolvingCreditFacility1500MillionCapacityMember
2019-08-31
0000021665
cl:Sevenyearnotesat0.50percentnumberMember
2019-03-31
0000021665
cl:AmendedDomesticRevolvingCreditFacility2650MillionCapacityMember
2018-11-30
0000021665
cl:Twoyearnotesat0.00percentMember
2019-12-31
0000021665
us-gaap:CommercialPaperMember
2019-12-31
0000021665
us-gaap:NotesPayableOtherPayablesMember
2018-12-31
0000021665
us-gaap:CommercialPaperMember
2018-12-31
0000021665
cl:FinanceLeaseObligationMember
2019-12-31
0000021665
us-gaap:NotesPayableOtherPayablesMember
2019-12-31
0000021665
us-gaap:CapitalLeaseObligationsMember
2018-12-31
0000021665
cl:Sevenyearnotesat0.50percentnumberMember
2019-01-01
2019-03-31
0000021665
cl:Fifteenyearnotesat1.375percentMember
2019-01-01
2019-03-31
0000021665
2019-08-01
2019-08-31
0000021665
cl:Twentyyearnotesat0.875percentMember
2019-01-01
2019-03-31
0000021665
cl:Twoyearnotesat0.00percentMember
2019-01-01
2019-03-31
0000021665
us-gaap:FairValueInputsLevel2Member
2019-12-31
0000021665
us-gaap:FairValueInputsLevel2Member
2018-12-31
0000021665
us-gaap:CarryingReportedAmountFairValueDisclosureMember
2018-12-31
0000021665
us-gaap:CarryingReportedAmountFairValueDisclosureMember
2019-12-31
0000021665
us-gaap:LongTermDebtMember
2019-12-31
0000021665
us-gaap:LongTermDebtMember
2018-12-31
0000021665
us-gaap:OtherAssetsMember
us-gaap:InterestRateContractMember
2018-12-31
0000021665
us-gaap:OtherCurrentLiabilitiesMember
us-gaap:ForeignExchangeContractMember
2018-12-31
0000021665
us-gaap:OtherLiabilitiesMember
us-gaap:ForeignExchangeContractMember
2019-12-31
0000021665
us-gaap:OtherCurrentAssetsMember
us-gaap:InterestRateContractMember
2018-12-31
0000021665
us-gaap:OtherCurrentAssetsMember
us-gaap:CommodityContractMember
2018-12-31
0000021665
us-gaap:OtherCurrentLiabilitiesMember
us-gaap:ForeignExchangeContractMember
2019-12-31
0000021665
us-gaap:OtherAssetsMember
us-gaap:ForeignExchangeContractMember
2019-12-31
0000021665
us-gaap:OtherAssetsMember
us-gaap:InterestRateContractMember
2019-12-31
0000021665
us-gaap:OtherCurrentAssetsMember
us-gaap:InterestRateContractMember
2019-12-31
0000021665
us-gaap:OtherCurrentAssetsMember
us-gaap:ForeignExchangeContractMember
2019-12-31
0000021665
us-gaap:OtherCurrentAssetsMember
us-gaap:ForeignExchangeContractMember
2018-12-31
0000021665
us-gaap:OtherLiabilitiesMember
us-gaap:InterestRateContractMember
2018-12-31
0000021665
us-gaap:OtherCurrentAssetsMember
2018-12-31
0000021665
us-gaap:OtherCurrentAssetsMember
2019-12-31
0000021665
us-gaap:OtherAssetsMember
us-gaap:ForeignExchangeContractMember
2018-12-31
0000021665
us-gaap:OtherLiabilitiesMember
us-gaap:InterestRateContractMember
2019-12-31
0000021665
us-gaap:OtherCurrentLiabilitiesMember
us-gaap:CommodityContractMember
2018-12-31
0000021665
us-gaap:OtherCurrentLiabilitiesMember
us-gaap:InterestRateContractMember
2019-12-31
0000021665
us-gaap:OtherCurrentLiabilitiesMember
us-gaap:CommodityContractMember
2019-12-31
0000021665
us-gaap:OtherCurrentAssetsMember
us-gaap:CommodityContractMember
2019-12-31
0000021665
us-gaap:OtherLiabilitiesMember
us-gaap:ForeignExchangeContractMember
2018-12-31
0000021665
us-gaap:OtherCurrentLiabilitiesMember
us-gaap:InterestRateContractMember
2018-12-31
0000021665
us-gaap:FairValueHedgingMember
2018-12-31
0000021665
us-gaap:DebtMember
us-gaap:CashFlowHedgingMember
2018-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
2018-12-31
0000021665
us-gaap:DebtMember
us-gaap:NetInvestmentHedgingMember
2018-12-31
0000021665
us-gaap:CommodityContractMember
us-gaap:NetInvestmentHedgingMember
2018-12-31
0000021665
us-gaap:NetInvestmentHedgingMember
2018-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueHedgingMember
2018-12-31
0000021665
us-gaap:CashFlowHedgingMember
2018-12-31
0000021665
us-gaap:CommodityContractMember
us-gaap:CashFlowHedgingMember
2018-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:CashFlowHedgingMember
2018-12-31
0000021665
us-gaap:InterestRateContractMember
us-gaap:NetInvestmentHedgingMember
2018-12-31
0000021665
us-gaap:CommodityContractMember
us-gaap:FairValueHedgingMember
2018-12-31
0000021665
us-gaap:InterestRateContractMember
us-gaap:CashFlowHedgingMember
2018-12-31
0000021665
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
2018-12-31
0000021665
us-gaap:DebtMember
us-gaap:FairValueHedgingMember
2018-12-31
0000021665
us-gaap:InterestRateContractMember
cl:InterestIncomeExpenseNetMember
2019-01-01
2019-12-31
0000021665
us-gaap:CommodityContractMember
cl:InterestIncomeExpenseNetMember
2019-01-01
2019-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:CostOfSalesMember
2019-01-01
2019-12-31
0000021665
us-gaap:InterestRateContractMember
cl:InterestIncomeExpenseNetMember
2018-01-01
2018-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:CashFlowHedgingMember
us-gaap:CostOfSalesMember
2018-01-01
2018-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2019-01-01
2019-12-31
0000021665
us-gaap:InterestRateContractMember
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2018-01-01
2018-12-31
0000021665
us-gaap:InterestRateContractMember
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2019-01-01
2019-12-31
0000021665
us-gaap:ForeignExchangeContractMember
cl:InterestIncomeExpenseNetMember
2018-01-01
2018-12-31
0000021665
us-gaap:ForeignExchangeContractMember
cl:InterestIncomeExpenseNetMember
2019-01-01
2019-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:CashFlowHedgingMember
cl:InterestIncomeExpenseNetMember
2018-01-01
2018-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2018-01-01
2018-12-31
0000021665
us-gaap:CostOfSalesMember
2019-01-01
2019-12-31
0000021665
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2019-01-01
2019-12-31
0000021665
us-gaap:InterestRateContractMember
us-gaap:CostOfSalesMember
2018-01-01
2018-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:CashFlowHedgingMember
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2018-01-01
2018-12-31
0000021665
us-gaap:InterestRateContractMember
us-gaap:CostOfSalesMember
2019-01-01
2019-12-31
0000021665
cl:InterestIncomeExpenseNetMember
2018-01-01
2018-12-31
0000021665
us-gaap:CommodityContractMember
us-gaap:CashFlowHedgingMember
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2018-01-01
2018-12-31
0000021665
us-gaap:CommodityContractMember
us-gaap:CashFlowHedgingMember
us-gaap:CostOfSalesMember
2018-01-01
2018-12-31
0000021665
us-gaap:CostOfSalesMember
2018-01-01
2018-12-31
0000021665
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2018-01-01
2018-12-31
0000021665
us-gaap:CommodityContractMember
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2019-01-01
2019-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:CostOfSalesMember
2018-01-01
2018-12-31
0000021665
cl:InterestIncomeExpenseNetMember
2019-01-01
2019-12-31
0000021665
us-gaap:CommodityContractMember
us-gaap:CashFlowHedgingMember
cl:InterestIncomeExpenseNetMember
2018-01-01
2018-12-31
0000021665
us-gaap:CommodityContractMember
us-gaap:CostOfSalesMember
2019-01-01
2019-12-31
0000021665
us-gaap:DebtMember
2018-01-01
2018-12-31
0000021665
us-gaap:ForeignExchangeContractMember
2019-01-01
2019-12-31
0000021665
us-gaap:CommodityContractMember
2018-01-01
2018-12-31
0000021665
us-gaap:DebtMember
2019-01-01
2019-12-31
0000021665
us-gaap:ForeignExchangeContractMember
2018-01-01
2018-12-31
0000021665
us-gaap:CommodityContractMember
2019-01-01
2019-12-31
0000021665
us-gaap:InterestRateContractMember
us-gaap:CashFlowHedgingMember
2019-12-31
0000021665
us-gaap:DebtMember
us-gaap:CashFlowHedgingMember
2019-12-31
0000021665
us-gaap:DebtMember
us-gaap:NetInvestmentHedgingMember
2019-12-31
0000021665
us-gaap:FairValueHedgingMember
2019-12-31
0000021665
us-gaap:NetInvestmentHedgingMember
2019-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
2019-12-31
0000021665
us-gaap:DebtMember
us-gaap:FairValueHedgingMember
2019-12-31
0000021665
us-gaap:CommodityContractMember
us-gaap:NetInvestmentHedgingMember
2019-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueHedgingMember
2019-12-31
0000021665
us-gaap:ForeignExchangeContractMember
us-gaap:CashFlowHedgingMember
2019-12-31
0000021665
us-gaap:InterestRateContractMember
us-gaap:NetInvestmentHedgingMember
2019-12-31
0000021665
us-gaap:CommodityContractMember
us-gaap:CashFlowHedgingMember
2019-12-31
0000021665
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
2019-12-31
0000021665
us-gaap:CashFlowHedgingMember
2019-12-31
0000021665
us-gaap:CommodityContractMember
us-gaap:FairValueHedgingMember
2019-12-31
0000021665
cl:TimeVestedRestrictedStockUnitsMember
2019-01-01
2019-12-31
0000021665
cl:TimeVestedRestrictedStockUnitsMember
2019-12-31
0000021665
cl:TimeVestedRestrictedStockUnitsMember
2018-12-31
0000021665
cl:PerformanceBasedRestrictedStockUnitsMember
2019-12-31
0000021665
cl:PerformanceBasedRestrictedStockUnitsMember
2019-01-01
2019-12-31
0000021665
cl:PerformanceBasedRestrictedStockUnitsMember
2018-12-31
0000021665
cl:PerformanceBasedRestrictedStockUnitsMember
cl:IncentiveStockPlansMember
2019-12-31
0000021665
cl:StockOptionPlansMember
2019-01-01
2019-12-31
0000021665
cl:Program2018Member
2018-06-18
0000021665
cl:StockOptionPlansMember
2017-01-01
2017-12-31
0000021665
cl:TimeVestedRestrictedStockUnitsMember
cl:IncentiveStockPlansMember
2017-01-01
2017-12-31
0000021665
cl:TimeVestedRestrictedStockUnitsMember
cl:IncentiveStockPlansMember
2019-01-01
2019-12-31
0000021665
cl:TimeVestedRestrictedStockUnitsMember
cl:IncentiveStockPlansMember
2019-12-31
0000021665
cl:StockOptionPlansMember
2019-12-31
0000021665
cl:TimeVestedRestrictedStockUnitsMember
cl:IncentiveStockPlansMember
2018-01-01
2018-12-31
0000021665
cl:StockOptionPlansMember
2018-01-01
2018-12-31
0000021665
2013-05-10
0000021665
cl:PerformanceBasedRestrictedStockUnitsMember
cl:IncentiveStockPlansMember
2019-01-01
2019-12-31
0000021665
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2017-12-31
0000021665
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-01-01
2018-12-31
0000021665
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-01-01
2019-12-31
0000021665
cl:OtherAssetsandLiabilitiesNetMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
cl:DefinedBenefitPlanDomesticDevelopedandEmergingMarketsEquityFundsMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
country:US
us-gaap:PensionPlansDefinedBenefitMember
2019-12-31
0000021665
cl:DefinedBenefitPlanDomesticDevelopedandEmergingMarketsEquityFundsMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
us-gaap:FairValueInputsLevel12And3Member
us-gaap:ForeignPlanMember
us-gaap:PensionPlansDefinedBenefitMember
2019-12-31
0000021665
cl:DefinedBenefitPlanMultiAssetFundsMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
cl:DefinedBenefitPlanFixedIncomeSecuritiesMember
us-gaap:FairValueInputsLevel2Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
cl:DefinedBenefitPlanGuaranteedInvestmentContractsMember
us-gaap:FairValueInputsLevel2Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
cl:DefinedBenefitPlanUSCommonStocksMember
us-gaap:FairValueInputsLevel1Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
us-gaap:FairValueInputsLevel12And3Member
country:US
us-gaap:PensionPlansDefinedBenefitMember
2019-12-31
0000021665
cl:DefinedBenefitPlanPooledFundsMember
us-gaap:FairValueInputsLevel1Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember
us-gaap:FairValueInputsLevel1Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
cl:OtherAssetsandLiabilitiesNetMember
country:US
us-gaap:PensionPlansDefinedBenefitMember
2019-12-31
0000021665
cl:DefinedBenefitPlanHedgeFundsMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember
us-gaap:FairValueInputsLevel1Member
country:US
us-gaap:PensionPlansDefinedBenefitMember
2019-12-31
0000021665
cl:DefinedBenefitPlanInternationalCommonStockMember
us-gaap:FairValueInputsLevel1Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
us-gaap:FairValueInputsLevel12And3Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
cl:OtherAssetsandLiabilitiesNetMember
us-gaap:ForeignPlanMember
us-gaap:PensionPlansDefinedBenefitMember
2019-12-31
0000021665
cl:DefinedBenefitPlanFixedIncomeFundsMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
cl:DefinedBenefitPlanDomesticDevelopedandEmergingMarketsEquityFundsMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:ForeignPlanMember
us-gaap:PensionPlansDefinedBenefitMember
2019-12-31
0000021665
us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember
us-gaap:FairValueInputsLevel1Member
us-gaap:ForeignPlanMember
us-gaap:PensionPlansDefinedBenefitMember
2019-12-31
0000021665
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
us-gaap:DefinedBenefitPlanRealEstateMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-12-31
0000021665
us-gaap:PensionPlansDefinedBenefitMember
2019-12-31
0000021665
cl:RealEstateandOtherInvestmentsMember
us-gaap:ForeignPlanMember
2019-12-31
0000021665
cl:RealEstateandOtherInvestmentsMember
country:US
2019-12-31
0000021665
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2017-01-01
2017-12-31
0000021665
cl:DefinedBenefitPlanDomesticDevelopedandEmergingMarketsEquityFundsMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
country:US
us-gaap:PensionPlansDefinedBenefitMember
2018-12-31
0000021665
cl:DefinedBenefitPlanPooledFundsMember
us-gaap:FairValueInputsLevel1Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
cl:OtherAssetsandLiabilitiesNetMember
us-gaap:ForeignPlanMember
us-gaap:PensionPlansDefinedBenefitMember
2018-12-31
0000021665
us-gaap:FairValueInputsLevel12And3Member
country:US
us-gaap:PensionPlansDefinedBenefitMember
2018-12-31
0000021665
us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember
us-gaap:FairValueInputsLevel1Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
cl:DefinedBenefitPlanDomesticDevelopedandEmergingMarketsEquityFundsMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
cl:DefinedBenefitPlanFixedIncomeFundsMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
cl:DefinedBenefitPlanGuaranteedInvestmentContractsMember
us-gaap:FairValueInputsLevel2Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
cl:DefinedBenefitPlanDomesticDevelopedandEmergingMarketsEquityFundsMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:ForeignPlanMember
us-gaap:PensionPlansDefinedBenefitMember
2018-12-31
0000021665
cl:DefinedBenefitPlanFixedIncomeSecuritiesMember
us-gaap:FairValueInputsLevel2Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
us-gaap:DefinedBenefitPlanRealEstateMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
cl:DefinedBenefitPlanMultiAssetFundsMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
cl:OtherAssetsandLiabilitiesNetMember
country:US
us-gaap:PensionPlansDefinedBenefitMember
2018-12-31
0000021665
cl:DefinedBenefitPlanUSCommonStocksMember
us-gaap:FairValueInputsLevel1Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember
us-gaap:FairValueInputsLevel1Member
us-gaap:ForeignPlanMember
us-gaap:PensionPlansDefinedBenefitMember
2018-12-31
0000021665
us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember
us-gaap:FairValueInputsLevel1Member
country:US
us-gaap:PensionPlansDefinedBenefitMember
2018-12-31
0000021665
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
cl:DefinedBenefitPlanInternationalCommonStockMember
us-gaap:FairValueInputsLevel1Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
cl:OtherAssetsandLiabilitiesNetMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
us-gaap:FairValueInputsLevel12And3Member
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
cl:DefinedBenefitPlanHedgeFundsMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-12-31
0000021665
us-gaap:FairValueInputsLevel12And3Member
us-gaap:ForeignPlanMember
us-gaap:PensionPlansDefinedBenefitMember
2018-12-31
0000021665
us-gaap:PensionPlansDefinedBenefitMember
2018-12-31
0000021665
2017-10-01
2017-12-31
0000021665
srt:MaximumMember
2019-01-01
2019-12-31
0000021665
country:CH
2018-01-01
2018-12-31
0000021665
srt:MinimumMember
2019-01-01
2019-12-31
0000021665
us-gaap:RestrictedStockUnitsRSUMember
2017-01-01
2017-12-31
0000021665
us-gaap:RestrictedStockUnitsRSUMember
2018-01-01
2018-12-31
0000021665
us-gaap:EmployeeStockOptionMember
2017-01-01
2017-12-31
0000021665
us-gaap:EmployeeStockOptionMember
2018-01-01
2018-12-31
0000021665
us-gaap:RestrictedStockUnitsRSUMember
2019-01-01
2019-12-31
0000021665
us-gaap:EmployeeStockOptionMember
2019-01-01
2019-12-31
0000021665
2014-12-31
0000021665
2014-12-01
2014-12-31
0000021665
srt:MinimumMember
2019-12-31
0000021665
srt:MaximumMember
2019-12-31
0000021665
2015-09-01
2015-09-30
0000021665
2017-07-31
0000021665
2019-04-01
2019-04-30
0000021665
us-gaap:OperatingSegmentsMember
srt:LatinAmericaMember
cl:OralPersonalAndHomeCareMember
2017-01-01
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:AsiaPacificMember
cl:OralPersonalAndHomeCareMember
2017-01-01
2017-12-31
0000021665
us-gaap:CorporateNonSegmentMember
2019-01-01
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:EuropeMember
cl:OralPersonalAndHomeCareMember
2017-01-01
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:LatinAmericaMember
cl:OralPersonalAndHomeCareMember
2018-01-01
2018-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:PetNutritionMember
2017-01-01
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:EuropeMember
cl:OralPersonalAndHomeCareMember
2018-01-01
2018-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:PetNutritionMember
2018-01-01
2018-12-31
0000021665
us-gaap:CorporateNonSegmentMember
2017-01-01
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:NorthAmericaMember
cl:OralPersonalAndHomeCareMember
2018-01-01
2018-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:OralPersonalAndHomeCareMember
2019-01-01
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:OralPersonalAndHomeCareMember
2017-01-01
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:AsiaPacificMember
cl:OralPersonalAndHomeCareMember
2018-01-01
2018-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:AfricaEurasiaMember
cl:OralPersonalAndHomeCareMember
2017-01-01
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:NorthAmericaMember
cl:OralPersonalAndHomeCareMember
2017-01-01
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:OralPersonalAndHomeCareMember
2018-01-01
2018-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:AfricaEurasiaMember
cl:OralPersonalAndHomeCareMember
2019-01-01
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:NorthAmericaMember
cl:OralPersonalAndHomeCareMember
2019-01-01
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:EuropeMember
cl:OralPersonalAndHomeCareMember
2019-01-01
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:AfricaEurasiaMember
cl:OralPersonalAndHomeCareMember
2018-01-01
2018-12-31
0000021665
us-gaap:CorporateNonSegmentMember
2018-01-01
2018-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:LatinAmericaMember
cl:OralPersonalAndHomeCareMember
2019-01-01
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:AsiaPacificMember
cl:OralPersonalAndHomeCareMember
2019-01-01
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:PetNutritionMember
2019-01-01
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:OralPersonalAndHomeCareMember
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:PetNutritionMember
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:OralPersonalAndHomeCareMember
2018-12-31
0000021665
us-gaap:CorporateNonSegmentMember
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:LatinAmericaMember
cl:OralPersonalAndHomeCareMember
2018-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:NorthAmericaMember
cl:OralPersonalAndHomeCareMember
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:AsiaPacificMember
cl:OralPersonalAndHomeCareMember
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:PetNutritionMember
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:AsiaPacificMember
cl:OralPersonalAndHomeCareMember
2018-12-31
0000021665
us-gaap:CorporateNonSegmentMember
2018-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:NorthAmericaMember
cl:OralPersonalAndHomeCareMember
2018-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:AfricaEurasiaMember
cl:OralPersonalAndHomeCareMember
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:LatinAmericaMember
cl:OralPersonalAndHomeCareMember
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:EuropeMember
cl:OralPersonalAndHomeCareMember
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:PetNutritionMember
2018-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:AfricaEurasiaMember
cl:OralPersonalAndHomeCareMember
2018-12-31
0000021665
us-gaap:CorporateNonSegmentMember
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:EuropeMember
cl:OralPersonalAndHomeCareMember
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:NorthAmericaMember
cl:OralPersonalAndHomeCareMember
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:AsiaPacificMember
cl:OralPersonalAndHomeCareMember
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:LatinAmericaMember
cl:OralPersonalAndHomeCareMember
2017-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:AfricaEurasiaMember
cl:OralPersonalAndHomeCareMember
2019-12-31
0000021665
us-gaap:OperatingSegmentsMember
srt:EuropeMember
cl:OralPersonalAndHomeCareMember
2018-12-31
0000021665
us-gaap:OperatingSegmentsMember
cl:OralPersonalAndHomeCareMember
2017-12-31
0000021665
us-gaap:OperatingIncomeLossMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-12-31
0000021665
us-gaap:SalesRevenueNetMember
2019-12-31
0000021665
us-gaap:OperatingIncomeLossMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-12-31
0000021665
us-gaap:CorporateNonSegmentMember
us-gaap:OperatingIncomeLossMember
2019-01-01
2019-12-31
0000021665
country:US
cl:OralPersonalAndHomeCareMember
2018-01-01
2018-12-31
0000021665
country:US
cl:PetNutritionMember
2018-01-01
2018-12-31
0000021665
country:US
cl:PetNutritionMember
2019-01-01
2019-12-31
0000021665
country:US
cl:PetNutritionMember
2017-01-01
2017-12-31
0000021665
us-gaap:OperatingIncomeLossMember
cl:GlobalGrowthandEfficiencyProgramMember
2017-01-01
2017-12-31
0000021665
country:US
cl:OralPersonalAndHomeCareMember
2019-01-01
2019-12-31
0000021665
country:US
cl:OralPersonalAndHomeCareMember
2017-01-01
2017-12-31
0000021665
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2019-01-01
2019-12-31
0000021665
us-gaap:AccumulatedTranslationAdjustmentMember
2019-01-01
2019-12-31
0000021665
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2018-01-01
2018-12-31
0000021665
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember
2017-01-01
2017-12-31
0000021665
us-gaap:AccumulatedTranslationAdjustmentMember
2018-01-01
2018-12-31
0000021665
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2017-01-01
2017-12-31
0000021665
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember
2018-01-01
2018-12-31
0000021665
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2019-01-01
2019-12-31
0000021665
us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember
2019-01-01
2019-12-31
0000021665
us-gaap:AccumulatedTranslationAdjustmentMember
2017-01-01
2017-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-03-31
0000021665
cl:GrossProfitMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-04-01
2018-06-30
0000021665
cl:GrossProfitMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-10-01
2019-12-31
0000021665
country:BR
2019-10-01
2019-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2018-10-01
2018-12-31
0000021665
2018-07-01
2018-09-30
0000021665
cl:GrossProfitMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-10-01
2018-12-31
0000021665
cl:GrossProfitMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-03-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2019-10-01
2019-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2018-04-01
2018-06-30
0000021665
cl:GrossProfitMember
cl:GlobalGrowthandEfficiencyProgramMember
2018-07-01
2018-09-30
0000021665
cl:GrossProfitMember
2019-01-01
2019-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2019-07-01
2019-09-30
0000021665
country:CH
2019-01-01
2019-12-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2018-01-01
2018-03-31
0000021665
cl:GrossProfitMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-07-01
2019-09-30
0000021665
country:CH
2019-10-01
2019-12-31
0000021665
country:BR
2019-01-01
2019-12-31
0000021665
2019-07-01
2019-09-30
0000021665
2018-04-01
2018-06-30
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2019-04-01
2019-06-30
0000021665
cl:GrossProfitMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-04-01
2019-06-30
0000021665
cl:GrossProfitMember
cl:GlobalGrowthandEfficiencyProgramMember
2019-01-01
2019-03-31
0000021665
cl:GlobalGrowthandEfficiencyProgramMember
2018-07-01
2018-09-30
0000021665
2019-04-01
2019-06-30
0000021665
2018-10-01
2018-12-31
0000021665
cl:AllowanceForDoubtfulAccountsAndEstimatedReturnsMember
2017-12-31
0000021665
us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember
2018-01-01
2018-12-31
0000021665
cl:AllowanceForDoubtfulAccountsAndEstimatedReturnsMember
2016-12-31
0000021665
cl:AllowanceForDoubtfulAccountsAndEstimatedReturnsMember
2019-01-01
2019-12-31
0000021665
cl:AllowanceForDoubtfulAccountsAndEstimatedReturnsMember
2017-01-01
2017-12-31
0000021665
cl:AllowanceForDoubtfulAccountsAndEstimatedReturnsMember
2018-12-31
0000021665
us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember
2017-01-01
2017-12-31
0000021665
us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember
2019-12-31
0000021665
cl:AllowanceForDoubtfulAccountsAndEstimatedReturnsMember
2019-12-31
0000021665
cl:AllowanceForDoubtfulAccountsAndEstimatedReturnsMember
2018-01-01
2018-12-31
0000021665
us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember
2016-12-31
0000021665
us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember
2018-12-31
0000021665
us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember
2019-01-01
2019-12-31
0000021665
us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember
2017-12-31
cl:country_and_territory
iso4217:USD
iso4217:USD
xbrli:shares
cl:employees
cl:business_segment
cl:Dividend
iso4217:EUR
xbrli:shares
xbrli:pure
cl:plan
cl:appeal
cl:case
cl:company
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(Mark One)
|
| |
☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2019
or
|
| |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to .
Commission File Number 1-644
COLGATE-PALMOLIVE COMPANY
(Exact name of registrant as specified in its charter) |
| | |
Delaware | 13-1815595 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
300 Park Avenue |
|
New York, | New York | 10022 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code 212-310-2000
Securities registered pursuant to Section 12(b) of the Act: |
| | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, $1.00 par value | CL | New York Stock Exchange |
0.000% Notes due 2021 | CL21A | New York Stock Exchange |
0.500% Notes due 2026 | CL26 | New York Stock Exchange |
1.375% Notes due 2034 | CL34 | New York Stock Exchange |
0.875% Notes due 2039 | CL39 | New York Stock Exchange |
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes ☐ No ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. |
| | | |
Large accelerated filer | ☒ | Accelerated filer | ☐ |
Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
The aggregate market value of Colgate-Palmolive Company Common Stock held by non-affiliates as of June 30, 2019 (the last business day of its most recently completed second quarter) was approximately $61.3 billion.
There were 855,029,777 shares of Colgate-Palmolive Company Common Stock outstanding as of January 31, 2020.
DOCUMENTS INCORPORATED BY REFERENCE:
|
| |
Documents | Form 10-K Reference |
Portions of Proxy Statement for the 2020 Annual Meeting of Stockholders | Part III, Items 10 through 14 |
Colgate-Palmolive Company
Table of Contents
|
| | |
Part I | | Page |
| | |
Item 1. | Business | |
Item 1A. | Risk Factors | |
Item 1B. | Unresolved Staff Comments | |
Item 2. | Properties | |
Item 3. | Legal Proceedings | |
Item 4. | Mine Safety Disclosures | |
| | |
Part II | | |
Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | |
Item 6. | Selected Financial Data | |
Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | |
Item 7A. | Quantitative and Qualitative Disclosures About Market Risk | |
Item 8. | Financial Statements and Supplementary Data | |
Item 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | |
Item 9A. | Controls and Procedures | |
Item 9B. | Other Information | |
| | |
Part III | | |
Item 10. | Directors, Executive Officers and Corporate Governance | |
Item 11. | Executive Compensation | |
Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | |
Item 13. | Certain Relationships and Related Transactions and Director Independence | |
Item 14. | Principal Accountant Fees and Services | |
| | |
Part IV | | |
Item 15. | Exhibits and Financial Statement Schedules | |
Item 16. | Form 10-K Summary | |
| | |
Signatures | |
PART I
ITEM 1. BUSINESS
(a) General Development of the Business
Colgate-Palmolive Company (together with its subsidiaries, the “Company” or “Colgate”) is a leading consumer products company whose products are marketed in over 200 countries and territories throughout the world. Colgate was founded in 1806 and incorporated under the laws of the State of Delaware in 1923.
For recent business developments and other information, refer to the information set forth under the captions “Management’s Discussion and Analysis of Financial Condition and Results of Operations–Executive Overview,” “– Outlook,” “–Results of Operations,” “–Restructuring and Related Implementation Charges” and “– Liquidity and Capital Resources” in Part II, Item 7 of this report.
(c) Narrative Description of the Business
The Company operates in two product segments: Oral, Personal and Home Care; and Pet Nutrition. Colgate is a leader in Oral Care with global leadership in the toothpaste and manual toothbrush categories according to market share data. Colgate’s Oral Care products include Colgate Maximum Cavity Protection, Colgate Total, Colgate Triple Action, Darlie Double Action, Colgate Max Fresh, Colgate Optic White, Colgate Whitening and Colgate Max White toothpastes, Colgate 360°, Colgate Extra Clean and Colgate Slim Soft manual toothbrushes and Colgate Plax, meridol and Colgate Total mouthwashes. Colgate’s Oral Care business also includes pharmaceutical products for dentists and other oral health professionals.
Colgate is a leader in many product categories of the Personal Care market with global leadership in liquid hand soap, which it sells under the Softsoap, Palmolive and Protex brands according to market share data. Colgate’s Personal Care products also include Protex, Palmolive and Irish Spring bar soaps, Palmolive, Sanex and Softsoap shower gels, Speed Stick, Sanex and Lady Speed Stick deodorants and antiperspirants, Filorga, Elta MD and PCA Skin skin health products and Palmolive and Caprice shampoos and conditioners.
Colgate manufactures and markets a wide array of products for the Home Care market, including Palmolive and Ajax dishwashing liquids and Fabuloso, Murphy’s Oil Soap and Ajax household cleaners. Colgate is a market leader in fabric conditioners with leading brands, including Suavitel in Latin America, Soupline in Europe, and Cuddly in the South Pacific, according to market share data.
Sales of Oral, Personal and Home Care products accounted for 46%, 20% and 18%, respectively, of the Company’s total worldwide Net sales in 2019. Geographically, Oral Care is a significant part of the Company’s business in Asia Pacific, comprising approximately 82% of Net sales in that region for 2019.
Colgate, through its Hill’s Pet Nutrition segment (“Hill’s” or “Pet Nutrition”), is a world leader in specialty pet nutrition products for dogs and cats with products marketed in over 80 countries and territories worldwide. Hill’s markets pet foods primarily under two brands. Hill’s Science Diet, which is called Hill’s Science Plan in Europe, is a range of products for everyday nutritional needs. Hill’s Prescription Diet is a range of therapeutic products to help nutritionally manage disease conditions in dogs and cats. Sales of Pet Nutrition products accounted for 16% of the Company’s total worldwide Net sales in 2019.
For more information regarding the Company’s worldwide Net sales by product category, refer to Note 1, Nature of Operations and Note 14, Segment Information to the Consolidated Financial Statements.
For additional information regarding market share data, see “Market Share Information” in Part II, Item 7 of this report.
Distribution; Raw Materials; Competition; Trademarks and Patents
The Company’s Oral, Personal and Home Care products are sold to a variety of traditional and eCommerce retailers, wholesalers and distributors worldwide. Pet Nutrition products are sold by authorized pet supply retailers, veterinarians and eCommerce retailers. The Company’s sales to Wal-Mart, Inc. and its affiliates represent approximately 11% of the Company’s Net sales in 2019. No other customer represents more than 10% of the Company’s Net sales. The Company supports its products with advertising, promotion and other marketing (with increasing emphasis on digital) to build awareness and trial of the Company’s products. The Company’s products are marketed by a direct sales force at individual operating subsidiaries or business units, and by distributors or brokers.
The majority of raw and packaging materials used in the Company’s products is purchased from other companies and is available from several sources. No single raw or packaging material represents, and no single supplier provides, a significant portion of the Company’s total material requirements. For certain materials, however, new suppliers may have to be qualified under industry, governmental and Colgate standards, which can require additional investment and take some period of time. Raw and packaging material commodities, such as resins, essential oils, pulp, tropical oils, tallow, poultry, corn and soybeans, are subject to market price variations. For further information regarding the impact of changes in commodity prices, see Item 1A, “Risk Factors - Volatility in material and other costs could adversely impact our profitability” and Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
The Company’s products are sold in a highly competitive global marketplace which has experienced increased trade concentration, the rapid growth of eCommerce, the integration of traditional and digital operations at key retailers and the growing presence of large-format retailers and discounters. Products similar to those produced and sold by the Company are available from multinational and local competitors in the U.S. and overseas. Certain of the Company’s competitors are larger and have greater resources than the Company. In certain geographies, the Company also faces strong local competitors, who may be more agile and have better local consumer insights than the Company. Private label brands sold by retailers are also a source of competition for certain of the Company’s products.
The retail landscape in many of the Company’s markets continues to be impacted by the rapid growth of eCommerce retailers, changing consumer preferences (as consumers increasingly shop online) and the emergence of alternative retail channels, such as subscription services and direct-to-customer businesses. The Company faces competition in several aspects of its business, including pricing, promotional activities, new product and brand introductions and expansion into new geographies and channels. Product quality, innovation, brand recognition, marketing capability and acceptance of new products and brands largely determine success in the Company’s operating segments.
The Company considers trademarks to be of material importance to its business. The Company follows a practice of seeking trademark protection in the U.S. and throughout the world where the Company’s products are sold. Principal global and regional trademarks include Colgate, Palmolive, elmex, meridol, Tom’s of Maine, Sorriso, Hello, Speed Stick, Lady Speed Stick, Softsoap, Irish Spring, Protex, Sanex, Filorga, Elta MD, PCA Skin, Ajax, Axion, Fabuloso, Soupline and Suavitel, as well as Hill’s Science Diet and Hill’s Prescription Diet. The Company’s rights in these trademarks endure for as long as they are used and/or registered. Although the Company actively develops and maintains a portfolio of patents, no single patent is considered significant to the business as a whole.
Environmental Matters
The Company has programs that are designed to ensure that its operations and facilities meet or exceed standards established by applicable environmental rules and regulations. Capital expenditures for environmental control facilities totaled approximately $46 million for 2019. For future years, expenditures are currently expected to be of a similar magnitude. For additional information regarding environmental matters refer to Note 13, Commitments and Contingencies, to the Consolidated Financial Statements.
Employees
As of December 31, 2019, the Company employed approximately 34,300 employees.
Information about our Executive Officers
The following is a list of executive officers as of February 21, 2020: |
| | | | | | |
Name | | Age | | Date First Elected Officer | | Present Title |
Ian Cook | | 67 | | 1996 | | Executive Chairman |
Noel R. Wallace | | 55 | | 2009 | | President and Chief Executive Officer |
Henning I. Jakobsen | | 59 | | 2017 | | Chief Financial Officer |
John J. Huston | | 65 | | 2002 | | Senior Vice President, Chief of Staff |
Daniel B. Marsili | | 59 | | 2005 | | Chief Human Resources Officer |
Patricia Verduin | | 60 | | 2011 | | Chief Technology Officer |
Jennifer M. Daniels | | 56 | | 2014 | | Chief Legal Officer and Secretary |
Philip G. Shotts | | 65 | | 2018 | | Vice President and Controller |
John W. Kooyman | | 55 | | 2019 | | Chief Marketing Officer |
Prabha Parameswaran | | 61 | | 2019 | | Group President, Global Innovation Group and Africa-Eurasia |
Panagiotis Tsourapas | | 55 | | 2019 | | Group President, Latin America and Asia Pacific |
Each of the executive officers listed above has served the registrant or its subsidiaries in various executive capacities for the past five years.
Under the Company’s By-Laws, the officers of the corporation hold office until their respective successors are chosen and qualified or until they have resigned, retired or been removed by the affirmative vote of a majority of the Board of Directors of the Company (the “Board”). There are no family relationships between any of the executive officers, and there is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was elected.
(e) Available Information
The Company’s website address is www.colgatepalmolive.com. The information contained on the Company’s website is not included as a part of, or incorporated by reference into, this Annual Report on Form 10-K. The Company makes available, free of charge, on its website its Annual Reports on Form 10-K, its Quarterly Reports on Form 10-Q, its interactive data files posted pursuant to Rule 405 of Regulation S-T, its Current Reports on Form 8-K and amendments to such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) as soon as reasonably practicable after the Company has electronically filed such material with, or furnished it to, the United States Securities and Exchange Commission (the “SEC”). Also available on the Company’s website are the Company’s Code of Conduct and Board Guidelines on Significant Corporate Governance Issues, the charters of the Committees of the Board, Specialized Disclosure Reports on Form SD, reports under Section 16 of the Exchange Act of transactions in Company stock by directors and executive officers and its proxy statements.
ITEM 1A. RISK FACTORS
In addition to the risks described elsewhere in this report, set forth below is a summary of the material risks to an investment in our securities. These risks are not the only ones we face. Additional risks not presently known to us or that we currently deem immaterial may also have an adverse effect on us. If any of these risks actually occur, our business, results of operations, cash flows and financial condition could be materially and adversely impacted, which might cause the value of our securities to decline.
We face risks associated with significant international operations, including exposure to foreign currency fluctuations.
We operate on a global basis serving consumers in more than 200 countries and territories with approximately 70% of our Net sales originating in markets outside the U.S. While geographic diversity helps to reduce our exposure to risks in any one country or part of the world, it also means that we face risks associated with significant international operations, including, but not limited to:
| |
▪ | changes in exchange rates for foreign currencies, which may reduce the U.S. dollar value of revenues, profits and cash flows from non-U.S. markets or increase our supply costs, as measured in U.S. dollars, in those markets; |
| |
▪ | exchange controls and other limits on our ability to import or export raw materials or finished product or to repatriate earnings from overseas; |
| |
▪ | political or economic instability, geopolitical events, environmental events, widespread health emergencies, such as the novel coronavirus or other pandemics or epidemics, natural disasters, or social or labor unrest; |
| |
▪ | changing macroeconomic conditions in our markets, including as a result of volatile commodity prices, including the price of oil; |
| |
▪ | lack of well-established, reliable and/or impartial legal systems in certain countries where we operate and difficulties in enforcing contractual, intellectual property or other legal rights; |
| |
▪ | foreign ownership and investment restrictions and the potential for nationalization or expropriation of property or other resources; and |
| |
▪ | changes to trade policies and agreements and other foreign or domestic legal and regulatory requirements, including those resulting in potentially adverse tax consequences or the imposition of and/or the increase in onerous trade restrictions and/or tariffs, sanctions, price controls, labor laws, travel or immigration restrictions, profit controls or other government controls. |
All of the foregoing risks could have a significant impact on our ability to sell our products on a competitive basis in international markets and may adversely affect our business, results of operations, cash flows and financial condition. In addition, a number of these risks may adversely impact consumer confidence and consumption, which could reduce sales volumes of our products or result in a shift in our product mix from higher margin to lower margin product offerings.
In addition, the impact of the United Kingdom’s exit from, and the related negotiations with, the European Union (commonly referred to as Brexit) are, at this time, unclear. Brexit has created legal, political and economic uncertainty, which could subject us to heightened risks in the region, including disruptions to trade and the free movement of goods, services and people to and from the United Kingdom, increased foreign exchange volatility with respect to the British pound and disruptions to our workforce and that of our suppliers and business partners. We do not, however, believe Brexit will have a material impact on our business, results of operations, cash flows or financial condition.
Furthermore, the recent imposition of tariffs and/or increase in tariffs on various products by the United States and other countries have introduced greater uncertainty with respect to trade policies and government regulations affecting trade between the United States and other countries and new and/or increased tariffs have subjected, and may continue in the future to subject, us to additional costs and expenditure of resources. Major developments in trade relations, including the imposition of new or increased tariffs by the United States and/or other countries, and any emerging nationalist trends in specific countries could alter the trade environment and consumer purchasing behavior which, in turn, could have a material effect on our business, results of operations, cash flows and financial condition.
In an effort to minimize the impact on earnings of foreign currency rate movements, we engage in a combination of selling price increases, where permitted, sourcing strategies, cost-containment measures and selective hedging of foreign currency transactions. However, the impact of these measures may not fully offset any negative impact of foreign currency rate movements on our business, results of operations, cash flows and financial condition.
Significant competition in our industry could adversely affect our business.
We face vigorous competition worldwide, including from strong local competitors and from other large, multinational companies, some of which may have greater resources than we do. In addition, the substantial growth in eCommerce has encouraged the entry of new competitors and business models.
We face competition in several aspects of our business, including pricing, promotional activities, new product introductions and expansion into new geographies and channels. Some of our competitors may spend more aggressively on or have more effective advertising and promotional activities than we do, introduce competing products more quickly and/or respond more effectively to changing consumer preferences and business and economic conditions. Such competition also extends to administrative and legal challenges of product claims and advertising. Our ability to compete also depends on the strength of our brands and on our ability to enforce and defend our intellectual property, including patent, trademark, copyright, trade secret and trade dress rights against infringement and legal challenges by competitors.
We may be unable to anticipate the timing and scale of such initiatives or challenges by competitors or to successfully respond to them, which could harm our business. In addition, the cost of responding to such initiatives and challenges, including management time, out-of-pocket expenses and price reductions, may affect our performance in the relevant period. A failure to compete effectively could adversely affect our business, results of operations, cash flows and financial condition.
Increasing dependence on key retailers in developed markets, changes in the policies of our retail trade customers, the emergence of alternative retail channels and the rapidly changing retail landscape may adversely affect our business.
Our products are sold in a highly competitive global marketplace which has experienced increased trade concentration and the growing presence of large-format retailers, discounters and eCommerce retailers. With the growing trend toward retail trade consolidation, the rapid growth of eCommerce and the integration of traditional and digital operations at key retailers, we are increasingly dependent on certain retailers, and some of these retailers have and may continue to have greater bargaining strength than we do. They have used and may continue to use this leverage to demand higher trade discounts, allowances or slotting fees, which could lead to reduced sales or profitability. The loss of a key customer or a significant reduction in sales to a key customer could adversely affect our business, results of operations, cash flows and financial condition. For additional information regarding our customers, see “Distribution; Raw Materials; Competition; Trademarks and Patents” in Item 1 “Business.”
We also have been and may continue to be negatively affected by changes in the policies or practices of our retail trade customers, such as inventory de-stocking, limitations on access to shelf space, delisting of our products, environmental or sustainability initiatives and other conditions. For example, a determination by a key retailer that any of our ingredients should not be used in certain consumer products or that our packaging does not comply with certain environmental standards or initiatives could adversely impact our business, results of operations, cash flows and financial condition. In addition, “private label” products sold by our retail customers, which are typically sold at lower prices than branded products, are a source of competition for certain of our products.
In addition, the retail landscape in many of our markets continues to be impacted by the rapid growth of eCommerce retailers, changing consumer preferences (as consumers increasingly shop online) and the emergence of alternative retail channels, such as subscription services and direct-to-customer businesses. The rapid growth in eCommerce and the emergence of alternative retail channels have created and may continue to create pricing pressures and/or adversely affect our relationships with our key retailers. If we are not successful in adapting or effectively reacting to changes in consumer preferences and market dynamics and/or expanding sales through eCommerce retailers and other alternative retail channels, our business, results of operations, cash flows and financial condition could be adversely affected.
Our business is subject to legal and regulatory risks in the U.S. and abroad.
Our business is subject to extensive legal and regulatory requirements in the U.S. and abroad. Such legal and regulatory requirements apply to most aspects of our products, including their development, ingredients, formulation, manufacture, packaging content, labeling, storage, transportation, distribution, export, import, advertising, sale and environmental impact. U.S. federal authorities, including the U.S. Food and Drug Administration (the “FDA”), the Federal Trade Commission, the Consumer Product Safety Commission and the Environmental Protection Agency, regulate different aspects of our business, along with parallel authorities at the state and local levels and comparable authorities overseas. In addition, our selling practices are regulated by competition law authorities in the U.S. and abroad.
New or more stringent legal or regulatory requirements, or more restrictive interpretations of existing requirements, could adversely impact our business, results of operations, cash flows and financial condition. For example, from time to time, various regulatory authorities in Europe, the U.S. and other countries review the use of various ingredients and packaging content in consumer products. A decision by a regulatory or governmental authority that any ingredient or packaging content in our products should be restricted or should otherwise be newly regulated, could adversely impact our business and reputation, as could negative reactions by our consumers, trade customers or non-governmental organizations to our current or prior use of such ingredients or packaging. Additionally, an inability to develop new or reformulated products containing alternative ingredients, to obtain regulatory approval of such products on a timely basis or to effectively market and sell such products could likewise adversely affect our business.
Because of our extensive international operations, we could be adversely affected by violations of worldwide anti-bribery laws, including those that prohibit companies and their intermediaries from making improper payments to government officials or other third parties for the purpose of obtaining or retaining business, such as the U.S. Foreign Corrupt Practices Act (the “FCPA”), and laws that prohibit commercial bribery. While our policies mandate compliance with these anti-bribery laws, we cannot provide assurance that our internal control policies and procedures will always protect us from reckless or criminal acts committed by our employees, joint venture partners or agents. Violations of these laws, or allegations of such violations, could disrupt our business and adversely affect our reputation and our business, results of operations, cash flows and financial condition.
While it is our policy and practice to comply with all legal and regulatory requirements applicable to our business, a finding that we are in violation of, or out of compliance with, applicable laws or regulations could subject us to civil remedies, including fines, damages, injunctions or product recalls, or criminal sanctions, any of which could adversely affect our business, results of operations, cash flows and financial condition. Even if a claim is unsuccessful, is without merit or is not fully pursued, the cost of responding to such a claim, including management time and out-of-pocket expenses, and the negative publicity surrounding such assertions regarding our products, processes or business practices could adversely affect our reputation, brand image and our business, results of operations, cash flows and financial condition. For information regarding our legal and regulatory matters, see Item 3 “Legal Proceedings” and Note 13, Commitments and Contingencies to the Consolidated Financial Statements.
The growth of our business depends on the successful identification, development and launch of innovative new products.
Our growth depends on the continued success of existing products, the successful identification, development and launch of innovative new and differentiated products and the expansion into adjacent categories, channels of distribution or geographies. Our ability to launch new products, to sustain existing products and to expand into adjacent categories, channels of distribution or geographies is affected by whether we can successfully:
| |
▪ | identify, develop and fund technological innovations; |
| |
▪ | obtain and maintain necessary intellectual property protection and avoid infringing intellectual property rights of others; |
| |
▪ | obtain approvals and registrations of regulated products, including from the FDA and other regulatory bodies in the U.S. and abroad; and |
| |
▪ | anticipate and quickly respond to consumer needs and preferences. |
The identification, development and introduction of innovative new products involves considerable costs and effort, and any new product may not generate sufficient customer and consumer interest and sales to become a profitable product or to cover the costs of its development and promotion. Our ability to achieve a successful launch of a new product could also be adversely affected by preemptive actions taken by competitors in response to the launch, such as increased promotional activities and advertising. In addition, new products may not be accepted quickly or significantly in the marketplace.
Our ability to quickly innovate and to adapt our products to meet evolving consumer preferences is an essential part of our business strategy. The failure to develop and launch successful new products could hinder the growth of our business and any delay in the development or launch of a new product could result in us not being the first to market, which could compromise our competitive position and adversely affect our business, results of operations, cash flows and financial condition.
If, in the course of identifying or developing new products, we are found to have infringed the trademark, trade secret, copyright, patent or other intellectual property rights of others, directly or indirectly, through the use of third-party ideas or technologies, such a finding could adversely affect our ability to develop innovative new products and adversely affect our business, results of operations, cash flows and financial condition. Even if we are not found to infringe a third party’s intellectual property rights, claims of infringement could adversely affect us, including by increasing costs and by delaying the launch of new products.
Damage to our reputation could have an adverse effect on our business.
Maintaining our strong reputation with consumers and our trade partners globally is critical to selling our branded products. Accordingly, we devote significant time and resources to programs designed to protect and preserve our reputation, such as our Ethics and Compliance, Sustainability, Brand Protection and Product Safety, Regulatory and Quality initiatives. Negative publicity about us, our brands, our products, our supply chain, our ingredients, our packaging or our employees, whether or not deserved, could jeopardize our reputation. Such negative publicity could relate to, among other things, health concerns, threatened or pending litigation or regulatory proceedings, environmental impacts (including packaging, energy and water use and waste management) or other sustainability or policy issues. In addition, widespread use of digital and social media by consumers has greatly increased the accessibility of information and the speed of its dissemination. Negative publicity, posts or comments on social media about us, our brands, our products, our packaging or our employees, whether true or untrue, could damage our brands and our reputation. The success of our brands could also suffer if our marketing initiatives do not have the desired impact on a brand’s image or its ability to attract consumers.
Additionally, due to the scale and scope of our business, we must rely on relationships with third parties, including our suppliers, distributors, contractors, joint venture partners and other external business partners, for certain functions. While we have policies and procedures for managing these relationships, they inherently involve a lesser degree of control over business operations, governance and compliance, thereby potentially increasing our reputational and legal risk.
In addition, third parties sell counterfeit versions of our products, which are inferior or may pose safety risks. As a result, consumers of our brands could confuse our products with these counterfeit products, which could cause them to refrain from purchasing our brands in the future and in turn could impair our brand equity and adversely affect our business, results of operations, cash flows and financial condition.
Damage to our reputation or loss of consumer confidence in our products for these or any other reasons could adversely affect our business, results of operations, cash flows and financial condition, as well as require resources to rebuild our reputation.
There is no guarantee that our ongoing efforts to reduce costs will be successful.
One way that we generate funds needed to support the growth of our business is through our continuous, Company-wide initiatives to lower costs and increase effective asset utilization, which we refer to as our funding-the-growth initiatives. These initiatives are designed to reduce costs associated with direct materials, indirect expenses, distribution and logistics, and advertising and promotional materials, among other things. The achievement of our funding-the-growth goals depends on our ability to successfully identify and realize additional savings opportunities. Events and circumstances, such as financial or strategic difficulties, delays and unexpected costs may occur that could result in our not realizing any or all of the anticipated benefits or our not realizing the anticipated benefits on our expected timetable. If we are unable to realize the anticipated savings of our funding-the-growth initiatives, our ability to fund other initiatives and achieve our profitability goals may be adversely affected. Any failure to implement our funding-the-growth initiatives in accordance with our expectations could adversely affect our business, results of operations, cash flows and financial condition. For additional information regarding our funding-the-growth initiatives, refer to Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Executive Overview.”
Volatility in material and other costs could adversely impact our profitability.
Raw and packaging material commodities, such as resins, essential oils, pulp, tropical oils, tallow, poultry, corn and soybeans, are subject to market price variations. Increases in the costs and/or a reduction in the availability of commodities, energy and transportation and other necessary services have affected and may continue to adversely affect our profit margins. If commodity and other cost increases continue in the future and we are unable to pass along such higher costs in the form of price increases, achieve cost efficiencies, such as in manufacturing and distribution, or otherwise manage the exposure through sourcing strategies, ongoing productivity initiatives and the limited use of commodity hedging contracts, our business, results of operations, cash flows and financial condition could be adversely impacted. In addition, even if we are able to increase the prices of our products in response to commodity and other cost increases, we may not be able to sustain the price increases. Also, sustained price increases may lead to declines in volume as competitors may not adjust their prices or consumers may decide not to pay higher prices, which could lead to sales declines and loss of market share and could adversely affect our business, results of operations, cash flows and financial condition. See “Disruption in our global supply chain or key office facilities could adversely impact our business” below for additional information.
Our success depends upon our ability to attract and retain key employees and the succession of senior management.
Our success largely depends on the performance of our management team and other key employees. If we are unable to attract and retain talented, highly qualified senior management and other key people, our business, results of operations, cash flows and financial condition could be adversely affected. Successfully executing organizational change, including management transitions at leadership levels of the Company and succession plans for senior management, is critical to our business success. While we follow a disciplined, ongoing succession planning process and have succession plans in place for senior management and other key executives, these do not guarantee that the services of qualified senior executives will continue to be available to us at particular moments in time. Further, changes in immigration laws and policies could also make it more difficult for us to recruit or relocate highly skilled technical, professional and management personnel to meet our business needs.
Legal claims and proceedings could adversely impact our business.
As a global company serving consumers in more than 200 countries and territories, we may be subject to a wide variety of legal claims and proceedings, including disputes relating to intellectual property, contracts, product liability, marketing, advertising, foreign exchange controls, antitrust and trade regulation, as well as labor and employment, pension, data privacy and security, environmental and tax matters and consumer class actions. Regardless of their merit, these claims can require significant time and expense to investigate and defend. Since litigation is inherently uncertain, there is no guarantee that we will be successful in defending ourselves against such claims or proceedings, or that our assessment of the materiality of these matters, including any reserves taken in connection therewith, will be consistent with the ultimate outcome of such matters. In addition, if one of our products, or an ingredient contained in our products, is perceived or found to be defective or unsafe, we may need to recall or reformulate some of our products. Whether or not a legal claim or proceeding is successful, or a recall or reformulation is required, such assertions could have an adverse effect on our business, results of operations, cash flows and financial condition, and the negative publicity surrounding them could harm our reputation and brand image. The resolution of, or increase in the reserves taken in connection with, one or more of these matters in any reporting period could have a material adverse effect on our business, results of operations, cash flows and financial condition for that period. See Item 3 “Legal Proceedings” and Note 13, Commitments and Contingencies to the Consolidated Financial Statements for additional information on certain of our legal claims and proceedings.
Disruption in our global supply chain or key office facilities could adversely impact our business.
We are engaged in manufacturing and sourcing of products and materials on a global scale. Our operations and those of our suppliers or contract manufacturers could be disrupted by a number of factors, including, but not limited to:
| |
▪ | widespread health emergencies, such as the novel coronavirus or other pandemics or epidemics; |
| |
▪ | strikes and other labor disputes; |
| |
▪ | disruptions in logistics; |
| |
▪ | loss or impairment of key manufacturing sites; |
| |
▪ | loss of key suppliers or contract manufacturers; |
| |
▪ | supplier capacity constraints; |
| |
▪ | raw material and product quality or safety issues; |
| |
▪ | industrial accidents or other occupational health and safety issues; |
| |
▪ | the impact on our suppliers of tighter credit or capital markets; |
| |
▪ | the lack of availability of qualified personnel, such as truck drivers; |
| |
▪ | governmental incentives and controls (including import and export restrictions, such as new or increased tariffs, sanctions, quotas or trade barriers); and |
| |
▪ | natural disasters, including climatic events (including any potential effect of climate change) and earthquakes, acts of war or terrorism, political unrest or uncertainty, fires or explosions and other external factors over which we have no control. |
In addition, we purchase certain key raw and packaging materials from single-source suppliers or a limited number of suppliers and new suppliers may have to be qualified under industry, governmental and Colgate standards, which can require additional investment and take a significant period of time.
We believe that the supplies of raw materials needed to manufacture our products are adequate. In addition, we have business continuity and contingency plans in place for key manufacturing sites and the supply of raw and packaging materials. Nonetheless, a significant disruption to the manufacturing or sourcing of products or materials for any reason, including those mentioned above, could interrupt product supply and, if not remedied, could have an adverse impact on our business, results of operations, cash flows and financial condition.
In addition, as a result of our global shared service organizational model, certain of our functions, such as marketing, payroll, finance and accounting, customer service and logistics, and human resources, are concentrated in key office facilities. A significant disruption to any of our key office facilities for any reason, including those mentioned above, could adversely affect our business, results of operations, cash flows and financial condition.
A cyber-security incident, data breach or a failure of a key information technology system could adversely impact our business.
We rely extensively on information technology systems (“IT Systems”), including some which are managed, hosted, provided and/or used by third parties, including cloud-based service providers, and their vendors, in order to conduct our business. Our uses of these systems include, but are not limited to:
| |
▪ | communicating within our company and with other parties, including our customers and consumers; |
| |
▪ | ordering and managing materials from suppliers; |
| |
▪ | converting materials to finished products; |
| |
▪ | receiving and processing orders from, shipping products to and invoicing our customers and consumers; |
| |
▪ | marketing products to consumers; |
| |
▪ | collecting, storing, transferring and/or processing customer, consumer, employee, vendor, investor and other stakeholder information and personal data, including, but not limited to, such data from residents of the European Union who are covered by the General Data Protection Regulation, which went into effect on May 25, 2018, and residents of the State of California who are covered by the California Consumer Privacy Act of 2018, which went into effect on January 1, 2020; |
| |
▪ | processing transactions, including but not limited to employee payroll, employee and retiree benefits and payments to customers and vendors; |
| |
▪ | hosting, processing and sharing confidential and proprietary research, intellectual property, business plans and financial information; |
| |
▪ | summarizing and reporting results of operations, including financial reporting; |
| |
▪ | managing our banking and other cash liquidity systems and platforms; |
| |
▪ | complying with legal, regulatory and tax requirements; |
| |
▪ | providing data security; and |
| |
▪ | handling other processes involved in managing our business. |
Although we have a broad array of information security measures in place, our IT Systems, including those of third-party service providers with whom we have contracted, have been, and will likely continue to be, subject to computer viruses or other malicious codes, unauthorized access attempts, phishing and other cyber-attacks. Cyber-attacks and other cyber incidents are occurring more frequently, are constantly evolving in nature, are becoming more sophisticated and are being made by groups, individuals and nation states with a wide range of expertise and motives. Such cyber-attacks and cyber incidents can take many forms, including cyber extortion, social engineering, password theft or introduction of viruses or malware, such as ransomware through phishing emails. We cannot guarantee that our security efforts will prevent breaches or breakdowns of our, or our third-party service providers’, IT Systems since the techniques used in these attacks change frequently and may be difficult to detect for periods of time. In addition, although we have policies and procedures in place to ensure that all personal information collected by us or our third-party service providers is securely maintained, data breaches due to human error or intentional or unintentional conduct have occurred and likely will continue to occur. Although we have seen no material impact on our business operations from the cyber-security attacks and data breaches we have experienced to date, if we suffer a loss or disclosure of confidential business or stakeholder information as a result of a breach of our IT Systems, including those of third-party service providers with whom we have contracted, we may suffer reputational, competitive and/or business harm, incur significant costs and be subject to government investigations, litigation, fines and/or damages, which may adversely impact our business, results of operations, cash flows and financial condition.
Furthermore, while we have disaster recovery and business continuity plans in place, if our IT Systems are damaged, breached or cease to function properly for any reason, including the poor performance of, failure of or cyber-attack on third-party service providers, catastrophic events, power outages, cyber-security breaches, network outages, failed upgrades or other similar events and, if the disaster recovery and business continuity plans do not effectively resolve such issues on a timely basis, we may suffer interruptions in our ability to manage or conduct business as well as reputational harm, and may be subject to governmental investigations and litigation, any of which may adversely impact our business, results of operations, cash flows and financial condition.
Uncertain global economic conditions, disruptions in the credit markets or changes to our credit ratings may adversely affect our business.
Uncertain global economic conditions could adversely affect our business. Unfavorable global economic conditions, such as a recession, economic slowdown and/or continued reduced category growth rates, have impacted and could continue to negatively impact our business and could result in declining revenues, profitability and cash flows. Although we continue to devote significant resources to support our brands and market our products at multiple price points, during periods of economic uncertainty consumers may reduce consumption or switch to “private label” or economy brands, which could reduce sales volumes of our products or result in a shift in our product mix from higher margin to lower margin product offerings. Additionally, our retailers may be impacted and they may increase pressure on our selling prices or increase promotional activity for lower-priced or value offerings as they seek to maintain sales volumes and margins.
While we currently generate significant cash flows from ongoing operations and have access to global credit markets through our various financing activities, a disruption in the credit markets, interest rate increases or changes to our credit ratings could negatively impact the availability or cost of funding. Reduced access to credit or increased costs could adversely affect our liquidity and capital resources or significantly increase our cost of capital. In addition, if any financial institutions that hold our cash or other investments or that are parties to our undrawn revolving credit facilities supporting our commercial paper programs or other financing arrangements, such as interest rate, foreign exchange or commodity hedging instruments, were to declare bankruptcy or become insolvent, they may be unable to perform under their agreements with us. This could leave us with reduced borrowing capacity or unhedged against certain interest rate, foreign currency or commodity price exposures. In addition, tighter credit markets may lead to business disruptions for certain of our suppliers, contract manufacturers or trade customers which could, in turn, adversely impact our business, results of operations, cash flows and financial condition.
We have pursued and may continue to pursue acquisitions and divestitures, which could adversely impact our business.
We have pursued and may continue to pursue acquisitions of brands, businesses or technologies from third parties. Acquisitions and their pursuit involve numerous potential risks, including, among other things:
| |
▪ | realizing the full extent of the expected benefits or synergies as a result of a transaction, within the anticipated time frame, or at all; |
| |
▪ | successfully integrating the operations, technologies, services, products and systems of the acquired brands or businesses in an effective, timely and cost-efficient manner; |
| |
▪ | receiving necessary consents, clearances and approvals in connection with a transaction; |
| |
▪ | diverting management’s attention from other business priorities; |
| |
▪ | successfully operating in new lines of business, channels of distribution or markets; |
| |
▪ | retaining key employees, partners, suppliers and customers of the acquired business; |
| |
▪ | conforming standards, controls, procedures and policies of the acquired business with our own; |
| |
▪ | developing or launching products with acquired technologies; and |
| |
▪ | other unanticipated problems or liabilities. |
Moreover, acquisitions could result in substantial additional debt, exposure to contingent liabilities, such as litigation or earn-out obligations, the potential impairment of goodwill or other intangible assets, or transaction costs. Any of these risks, should they materialize, could adversely impact our business, results of operations, cash flows and financial condition.
We also may periodically divest brands or businesses. These divestitures may adversely impact our business, results of operations, cash flows and financial condition if we are unable to offset the dilutive impacts from the loss of revenue associated with the divested brands or businesses, or otherwise achieve the anticipated benefits or cost savings from the divestitures. In addition, businesses under consideration for, or otherwise subject to, divestiture may be adversely impacted prior to the divestiture, which could negatively impact our business, results of operations, cash flows and financial condition.
Tax matters, including changes in tax rates, disagreements with taxing authorities and imposition of new taxes could negatively impact our business.
We are subject to taxes in the U.S. and in the foreign jurisdictions where we do business. Due to economic and political conditions, tax rates in the U.S. and various foreign jurisdictions have been and may be subject to significant change. Changes in the mix of our earnings from countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in tax laws, including how existing tax laws are interpreted or enforced, or contemplated changes in long-standing tax principles, if finalized and adopted, could adversely impact our future effective tax rate and business, results of operations, cash flows and financial condition. For example, longstanding international tax norms that determine each country’s jurisdiction to tax cross-border international trade are evolving as a result of the Base Erosion and Profit Shifting reporting requirements (“BEPS”) recommended by the G8, G20 and Organization for Economic Cooperation and Development. In connection with BEPS, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in countries outside of the U.S. As this and other tax laws and related regulations change, our business, results of operations, cash flows and financial condition could be materially impacted. For more information regarding U.S. tax reform, see Note 11, Income Taxes to the Consolidated Financial Statements.
Furthermore, we are subject to regular reviews, examinations and audits by the Internal Revenue Service and other taxing authorities with respect to taxes inside and outside of the U.S. Although we believe our tax positions are reasonable, if a taxing authority disagrees with the positions we have taken, we could face additional tax liabilities, including interest and penalties, in excess of reserves. The payment of such additional amounts upon final adjudication of any disputes could adversely impact our business, results of operations, cash flows and financial condition.
Climate change may have an adverse impact on our business and results of operations.
It has been reported that carbon dioxide and other greenhouse gases in the atmosphere have an adverse impact on global temperatures, weather patterns and the frequency and severity of extreme weather and natural disasters. The predicted effects of climate change may also exacerbate challenges regarding the availability and quality of water. In addition, concern over climate change may result in new or additional legal and regulatory requirements to reduce or mitigate the effects of climate change on the environment. Despite our sustainability efforts, any failure to achieve our sustainability goals to reduce our impact on the environment or the perception (whether or not valid) that we have failed to act responsibly with respect to the environment or to effectively respond to new or additional legal or regulatory requirements regarding climate change could result in adverse publicity and adversely affect our business and reputation. There is also increased focus, including by governmental and non-governmental organizations, investors, customers, consumers and other stakeholders on these and other sustainability matters, including deforestation and the use of plastic, energy and water. Our reputation could be damaged if we do not (or are perceived not to) act responsibly with respect to sustainability matters, which could adversely affect our business, results of operations, cash flows and financial condition.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
ITEM 2. PROPERTIES
The Company owns or leases approximately 320 properties, which include manufacturing, distribution, research and office facilities worldwide. Our corporate headquarters is located in leased property at 300 Park Avenue, New York, New York.
In the U.S., the Company operates in approximately 60 properties, of which 13 are owned. Major U.S. manufacturing and warehousing facilities used by the Oral, Personal and Home Care product segment of our business are located in Greenwood, South Carolina; Morristown, Tennessee; and Cambridge, Ohio. The Pet Nutrition segment has major manufacturing and warehousing facilities in Bowling Green, Kentucky; Emporia, Kansas; Richmond, Indiana; and Topeka, Kansas.
Overseas, the Company operates in approximately 260 properties, of which 60 are owned, in over 80 countries. Major overseas manufacturing and warehousing facilities used by the Oral, Personal and Home Care product segment of our business are located in Australia, Brazil, China, Colombia, France, Greece, Guatemala, India, Italy, Mexico, Poland, South Africa, Thailand, Turkey and Venezuela. The Pet Nutrition segment has major manufacturing and warehousing facilities in the Czech Republic and the Netherlands.
The primary research center for Oral and Personal Care products is located in Piscataway, New Jersey, the primary research center for Home Care products is located in Mexico and the primary research center for Pet Nutrition products is located in Topeka, Kansas. Our global data center is also located in Piscataway, New Jersey.
The Company has shared business service centers in India, Mexico and Poland, which are located in leased properties.
All of the facilities we operate are well maintained and adequate for the purpose for which they are intended.
ITEM 3. LEGAL PROCEEDINGS
As a global company serving consumers in more than 200 countries and territories, the Company is routinely subject to a wide variety of legal proceedings. These include disputes relating to intellectual property, contracts, product liability, marketing, advertising, foreign exchange controls, antitrust and trade regulation, as well as labor and employment, pension, data privacy and security, environmental and tax matters, and consumer class actions. Management proactively reviews and monitors the Company’s exposure to, and the impact of, environmental matters. The Company is party to various environmental matters and, as such, may be responsible for all or a portion of the cleanup, restoration and post-closure monitoring of several sites.
The Company establishes accruals for loss contingencies when it has determined that a loss is probable and that the amount of loss, or range of loss, can be reasonably estimated. Any such accruals are adjusted thereafter as appropriate to reflect changes in circumstances.
The Company also determines estimates of reasonably possible losses or ranges of reasonably possible losses in excess of related accrued liabilities, if any, when it has determined that a loss is reasonably possible and it is able to determine such estimates. For those matters disclosed below for which the amount of any potential losses can be reasonably estimated, the Company currently estimates that the aggregate range of reasonably possible losses in excess of any accrued liabilities is $0 to approximately $225 million (based on current exchange rates). The estimates included in this amount are based on the Company’s analysis of currently available information and, as new information is obtained, these estimates may change. Due to the inherent subjectivity of the assessments and the unpredictability of outcomes of legal proceedings, any amounts accrued or included in this aggregate amount may not represent the ultimate loss to the Company. Thus, the Company’s exposure and ultimate losses may be higher or lower, and possibly significantly so, than the amounts accrued or the range disclosed above.
Based on current knowledge, management does not believe that the ultimate resolution of loss contingencies arising from the matters discussed herein will have a material effect on the Company’s consolidated financial position or its ongoing results of operations or cash flows. However, in light of the inherent uncertainties noted above, an adverse outcome in one or more matters could be material to the Company’s results of operations or cash flows for any particular quarter or year.
Brazilian Matters
There are certain tax and civil proceedings outstanding, as described below, related to the Company’s 1995 acquisition of the Kolynos oral care business from Wyeth (the “Seller”).
The Brazilian internal revenue authority has disallowed interest deductions and foreign exchange losses taken by the Company’s Brazilian subsidiary for certain years in connection with the financing of the Kolynos acquisition. The tax assessments with interest, penalties and any court-mandated fees, at the current exchange rate, are approximately $152 million. This amount includes additional assessments received from the Brazilian internal revenue authority in April 2016 relating to net operating loss carryforwards used by the Company’s Brazilian subsidiary to offset taxable income that had also been deducted from the authority’s original assessments. The Company has been disputing the disallowances by appealing the assessments since October 2001. There is one case currently on appeal at the administrative level. In the event the Company is ultimately unsuccessful in this administrative appeal, further appeals are available within the Brazilian federal courts.
In September 2015, the Company lost one of its appeals at the administrative level and filed a lawsuit in Brazilian federal court. In February 2017, the Company lost an additional administrative appeal and filed a lawsuit in Brazilian federal court. In April 2019, the Company lost another administrative appeal and filed a lawsuit in Brazilian federal court. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that the disallowances are without merit and that the Company should ultimately prevail. The Company is challenging these disallowances vigorously.
In July 2002, the Brazilian Federal Public Attorney filed a civil action against the federal government of Brazil, Laboratorios Wyeth-Whitehall Ltda. (the Brazilian subsidiary of the Seller) and the Company, as represented by its Brazilian subsidiary, in the 6th. Lower Federal Court in the City of São Paulo, seeking to annul an April 2000 decision by the Brazilian Board of Tax Appeals that found in favor of the Seller’s Brazilian subsidiary on the issue of whether it had incurred taxable capital gains as a result of the divestiture of Kolynos. The action seeks to make the Company’s Brazilian subsidiary jointly and severally liable for any tax due from the Seller’s Brazilian subsidiary. The case has been pending since 2002, and the Lower Federal Court has not issued a decision. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that the Company should ultimately prevail in this action. The Company is challenging this action vigorously.
In December 2005, the Brazilian internal revenue authority issued to the Company’s Brazilian subsidiary a tax assessment with interest, penalties and any court-mandated fees of approximately $63 million, at the current exchange rate, based on a claim that certain purchases of U.S. Treasury bills by the subsidiary and their subsequent disposition during the period 2000 to 2001 were subject to a tax on foreign exchange transactions. The Company had been disputing the assessment within the internal revenue authority’s administrative appeals process. However, in November 2015, the Superior Chamber of Administrative Tax Appeals denied the Company’s final administrative appeal and the Company has filed a lawsuit in the Brazilian federal court. In the event the Company is unsuccessful in this lawsuit, further appeals are available within the Brazilian federal courts. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that the tax assessment is without merit and that the Company should ultimately prevail. The Company is challenging this assessment vigorously.
Competition Matters
Certain of the Company’s subsidiaries have historically been subject to investigations, and, in some cases, fines, by governmental authorities in a number of countries related to alleged competition law violations. Substantially all of these matters also involved other consumer goods companies and/or retail customers. The Company’s policy is to comply with antitrust and competition laws and, if a violation of any such laws is found, to take appropriate remedial action and to cooperate fully with any related governmental inquiry. The status as of December 31, 2019 of competition law matters pending against the Company during the year ended December 31, 2019 is set forth below.
| |
▪ | In December 2014, the French competition law authority found that 13 consumer goods companies, including the Company’s French subsidiary, exchanged competitively sensitive information related to the French home care and personal care sectors, for which the Company’s French subsidiary was fined $57 million. In addition, as a result of the Company’s acquisition of the Sanex personal care business in 2011 from Unilever N.V. and Unilever PLC (together with Unilever N.V., “Unilever”) pursuant to a Business and Share Sale and Purchase Agreement (the “Sale and Purchase Agreement”), the French competition law authority found that the Company’s French subsidiary, along with Hillshire Brands Company (formerly Sara Lee Corporation (“Sara Lee”)), were jointly and severally liable for fines of $25 million assessed against Sara Lee’s French subsidiary. The Company is indemnified for these fines by Unilever pursuant to the Sale and Purchase Agreement. The fines were confirmed by the Court of Appeal in October 2016. The Company appealed the decision of the Court of Appeal on behalf of the Company and Sara Lee in the French Supreme Court. In March 2019, the French Supreme Court denied the Company’s appeal. |
| |
▪ | In July 2014, the Greek competition law authority issued a statement of objections alleging a restriction of parallel imports into Greece. The Company responded to this statement of objections. In July 2017, the Company received the decision from the Greek competition law authority in which the Company was fined $11 million. The Company appealed the decision to the Greek courts. In April 2019, the Greek courts affirmed the judgment against the Company’s Greek subsidiary, but reduced the fine to $10.5 and dismissed the case against Colgate-Palmolive Company. The Company’s Greek subsidiary has appealed the decision to the Greek Supreme Court. |
Talcum Powder Matters
The Company has been named as a defendant in civil actions alleging that certain talcum powder products that were sold prior to 1996 were contaminated with asbestos. Most of these actions involve a number of co-defendants from a variety of different industries, including suppliers of asbestos and manufacturers of products that, unlike the Company’s products, were designed to contain asbestos. As of December 31, 2019, there were 121 individual cases pending against the Company in state and federal courts throughout the United States, as compared to 239 cases as of December 31, 2018. During the year ended December 31, 2019, 110 new cases were filed and 228 cases were resolved by voluntary dismissal, dismissal by the court, judgment in the Company’s favor or settlement. During the year ended December 31, 2019, one case resulted in a jury verdict in favor of the Company after a trial, which is now pending appeal by the plaintiff, and one case resulted in an adverse jury verdict after a trial, which the Company is appealing. The value of the settlements and of the adverse jury verdict in the year presented was not material, either individually or in the aggregate, to such period’s results of operations.
The Company believes that a significant portion of its costs incurred in defending and resolving these claims will be covered by insurance policies issued by several primary, excess and umbrella insurance carriers, subject to deductibles, exclusions, retentions and policy limits.
While the Company and its legal counsel believe that these cases are without merit and intend to challenge them vigorously, there can be no assurances regarding the ultimate resolution of these matters. With the exception of the case where the Company received an adverse jury verdict, the range of reasonably possible losses in excess of accrued liabilities disclosed above does not include any amount relating to these cases because the amount of any possible losses from such cases currently cannot be reasonably estimated.
ERISA Matter
In June 2016, a putative class action claiming that residual annuity payments made to certain participants in the Colgate-Palmolive Company Employees’ Retirement Income Plan (the “Plan”) did not comply with the Employee Retirement Income Security Act was filed against the Plan, the Company and certain individuals in the United States District Court for the Southern District of New York. This action has been certified as a class action. The relief sought includes recalculation of benefits, pre- and post-judgment interest and attorneys’ fees. The Company is contesting this action vigorously. Since the amount of any potential loss from this case currently cannot be reasonably estimated, the range of reasonably possible losses in excess of accrued liabilities disclosed above does not include any amount relating to the case.
ITEM 4. MINE SAFETY DISCLOSURES
Not Applicable.
PART II
| |
ITEM 5. | MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES |
For information regarding the market for the Company’s common stock, including stock price performance graphs, refer to “Market Information” included in Part IV, Item 15 of this report. For information regarding the number of common shareholders of record, refer to “Historical Financial Summary” included in Part IV, Item 15 of this report. For information regarding the securities authorized for issuance under our equity compensation plans, refer to “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” included in Part III, Item 12 of this report.
Issuer Purchases of Equity Securities
On June 18, 2018, the Board authorized the repurchase of shares of the Company’s common stock having an aggregate purchase price of up to $5 billion under a new share repurchase program (the “2018 Program”), which replaced a previously authorized share repurchase program (the "2015 Program"). The Board also has authorized share repurchases on an ongoing basis to fulfill certain requirements of the Company’s compensation and benefit programs. The shares are repurchased from time to time in open market or privately negotiated transactions at the Company’s discretion, subject to market conditions, customary blackout periods and other factors.
The following table shows the stock repurchase activity for the three months in the quarter ended December 31, 2019: |
| | | | | | | | | | | | | |
Month | | Total Number of Shares Purchased(1) | | Average Price Paid per Share | | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2) | | Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs(3) (in millions) |
October 1 through 31, 2019 | | 1,174,592 |
| | $ | 69.14 |
| | 1,134,000 |
| | 3,366 |
|
November 1 through 30, 2019 | | 609,802 |
| | $ | 66.60 |
| | 608,630 |
| | 3,325 |
|
December 1 through 31, 2019 | | 672,010 |
| | $ | 67.92 |
| | 642,039 |
| | 3,282 |
|
Total | | 2,456,404 |
| | $ | 68.18 |
| | 2,384,669 |
| | |
|
_______
| |
(1) | Includes share repurchases under the 2018 Program and those associated with certain employee elections under the Company’s compensation and benefit programs. |
| |
(2) | The difference between the total number of shares purchased and the total number of shares purchased as part of publicly announced plans or programs is 71,735 shares, which represents shares deemed surrendered to the Company to satisfy certain employee elections under the Company’s compensation and benefit programs. |
| |
(3) | Includes approximate dollar value of shares that were available to be purchased under the publicly announced plans or programs that were in effect as of December 31, 2019. |
ITEM 6. SELECTED FINANCIAL DATA
Refer to the information set forth under the caption “Historical Financial Summary” included in Part IV, Item 15 of this report.
(Dollars in Millions Except Per Share Amounts)
| |
ITEM 7. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
Executive Overview
Colgate-Palmolive Company (together with its subsidiaries, “we,” the “Company” or “Colgate”) seeks to deliver strong, consistent business results and superior shareholder returns by providing consumers globally with products that make their lives healthier and more enjoyable.
To this end, we are tightly focused on two product segments: Oral, Personal and Home Care; and Pet Nutrition. Within these segments, we follow a closely defined business strategy to grow our key product categories and increase our overall market share. Within the categories in which we compete, we prioritize our efforts based on their capacity to maximize the use of the organization’s core competencies and strong global equities and to deliver sustainable long-term growth.
Operationally, we are organized along geographic lines with management teams having responsibility for the business and financial results in each region. We compete in more than 200 countries and territories worldwide with established businesses in all regions contributing to our sales and profitability. Approximately 70% of our Net sales are generated from markets outside the U.S., with approximately 50% of our Net sales coming from emerging markets (which consist of Latin America, Asia (excluding Japan), Africa/Eurasia and Central Europe). This geographic diversity and balance help to reduce our exposure to business and other risks in any one country or part of the world.
The Oral, Personal and Home Care product segment is managed geographically in five reportable operating segments: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia, all of which sell primarily to a variety of traditional and eCommerce retailers, wholesalers and distributors. Through Hill’s Pet Nutrition, we also compete on a worldwide basis in the pet nutrition market, selling products principally through authorized pet supply retailers, veterinarians and eCommerce retailers.
On an ongoing basis, management focuses on a variety of key indicators to monitor business health and performance. These indicators include net sales (including volume, pricing and foreign exchange components), organic sales growth (net sales growth excluding, the impact of foreign exchange, acquisitions, and divestments), a non-GAAP financial measure, and gross profit margin, operating profit, net income and earnings per share, in each case, on a GAAP and non-GAAP basis, as well as measures used to optimize the management of working capital, capital expenditures, cash flow and return on capital. In addition, we review market share data to assess how our brands are performing within their categories on a global and regional basis. The monitoring of these indicators and our Code of Conduct and corporate governance practices help to maintain business health and strong internal controls. For additional information regarding non-GAAP financial measures and the Company's use of market share data and the limitations of such data, see “Non-GAAP Financial Measures” and "Market Share Information" below.
To achieve our business and financial objectives, we are focused on innovating our core businesses; improving our brand building activities with an elevated brand purpose model and the use of equity advertising; innovating to gain market share in high growth segments and adjacencies; expanding into new channels and markets; maximizing growth online; and investing to drive consumption in growing populations. We continue to develop initiatives to build strong relationships with consumers, dental, veterinary and skin health professionals and traditional and eCommerce retailers. In addition, we continue to invest behind our brands, not just in terms of advertising, but also to build key growth capabilities in areas such as innovation and data and analytics. We also continue to broaden our eCommerce offerings, including direct-to-consumer and subscription services. We continue to believe that growth opportunities are greater in those areas of the world in which economic development and rising consumer incomes expand the size and number of markets for the Company’s products. We are also working to integrate our sustainability strategy across our organization.
We are also changing the way we work to drive growth and how we approach innovation to respond to the dynamic retail landscape and the evolving preferences of our customers and consumers. The retail landscape, the ease of new entrants into the market in many of our categories and the evolving preferences of our customers and consumers demand that we work differently and faster in an agile, authentic and culturally relevant manner to drive innovation.
(Dollars in Millions Except Per Share Amounts)
The investments needed to support growth are developed through continuous, Company-wide initiatives to lower costs and increase effective asset utilization. Through these initiatives, which are referred to as our funding-the-growth initiatives, we seek to become even more effective and efficient throughout our businesses. These initiatives are designed to reduce costs associated with direct materials, indirect expenses, distribution and logistics, and advertising and promotional materials, among other things, and encompass a wide range of projects, examples of which include raw material substitution, reduction of packaging materials, consolidating suppliers to leverage volumes and increasing manufacturing efficiency through SKU reductions and formulation simplification. We also continue to prioritize our investments in high growth segments within our Oral Care, Personal Care and Pet Nutrition businesses, including by expanding our portfolio in premium skin health.
(Dollars in Millions Except Per Share Amounts)
Significant Items Impacting Comparability
On September 19, 2019, the Company acquired Laboratoires Filorga Cosmétiques S.A. (“Filorga”), a skin health business, for cash consideration of €1,548 (approximately $1,712). Filorga is a premium anti-aging skin health brand focused primarily on facial care. The acquisition was financed with a combination of debt and cash. This acquisition is part of our strategy to focus on high growth segments within our Oral Care, Personal Care and Pet Nutrition businesses, including by expanding our portfolio in premium skin health. See Note 3, Acquisitions to the Consolidated Financial Statements for additional information.
In December 2019, the Swiss government enacted changes to its corporate tax regime, which included, among other items, the repeal of certain preferential tax regimes and an increase to the cantonal tax rate for future periods. Additionally, the government provided transition rules which allowed companies to record goodwill for tax purposes, partially offsetting the impact on cash taxes of the higher cantonal rate over the next ten years. As a result of these changes, the Company recorded an estimated net benefit of $29 to the Provision for income taxes.
In 2019, the Company received a favorable judgment regarding certain value-added tax previously paid in Brazil. As a result of the favorable judgment, during the fourth quarter of 2019, the Company filed an application with the Brazilian government to recover value-added tax previously paid and recorded a benefit of $30 pretax ($20 aftertax). The recovery will be utilized to offset corporate income tax payments in Brazil in future periods.
In January 2018, the Company acquired all of the outstanding equity interests of Physicians Care Alliance, LLC and Elta MD Holdings, Inc., professional skin health businesses, for aggregate cash consideration of approximately $730. See Note 3, Acquisitions to the Consolidated Financial Statements for additional information.
As a result of the enactment of the Tax Cuts and Jobs Act (the “TCJA” or “U.S. tax reform”), in the fourth quarter of 2017, the Company recorded a provisional charge of $275 based on its initial analysis of the TCJA using information and estimates available as of February 15, 2018, the date on which the Company filed its Annual Report on Form 10-K for the year ended December 31, 2017. During 2018, the Company finalized its assessment of the impact of the TCJA and recognized an additional tax expense of $80 reflecting the impact of transition tax guidance issued by the U.S. Treasury and the update of certain estimates and calculations based on information available through the end of 2018.
Our restructuring program, known as the “Global Growth and Efficiency Program,” concluded on December 31, 2019. The program’s initiatives were designed to help us ensure sustained solid worldwide growth in unit volume, organic sales, operating profit and earnings per share and to enhance our global leadership positions in our core businesses. Substantially all initiatives under the program were implemented as of December 31, 2019.
The initiatives under the Global Growth and Efficiency Program focused on the following areas:
| |
▪ | Expanding Commercial Hubs |
| |
▪ | Extending Shared Business Services and Streamlining Global Functions |
| |
▪ | Optimizing Global Supply Chain and Facilities |
Savings, substantially all of which have been realized, are projected to be in the range of $640 to $660 pretax ($580 to $590 aftertax) annually. Substantially all of the savings are expected to increase future cash flows. Total pretax charges resulting from the Global Growth and Efficiency Program were $1,854 pretax ($1,380 aftertax), in line with the previously disclosed range.
In 2019 and 2018, we incurred aftertax costs of $102 and $125, respectively, resulting from the Global Growth and Efficiency Program. For more information regarding the Global Growth and Efficiency Program, see “Restructuring and Related Implementation Charges” below and Note 4, Restructuring and Related Implementation Charges to the Consolidated Financial Statements.
(Dollars in Millions Except Per Share Amounts)
Effective January 1, 2019, as required by the Financial Accounting Standards Board ("FASB"), the Company adopted ASU No. 2016-02, "Leases (Topic 842)," which superseded Topic 840, "Leases," which was further modified in ASU No. 2018-10, "Codification Improvements to Topic 842, Leases," ASU No. 2018-11, "Leases (Topic 842) Targeted Improvements" and ASU No. 2019-01 "Leases (Topic 842) Codification Improvements" to clarify the implementation guidance. The new accounting standard required the recognition on the balance sheet of right-of-use assets and leases liabilities for all long-term leases, including operating leases. The Company elected the optional transition method and adopted the new guidance on January 1, 2019, on a modified retrospective basis, with no restatement of prior period amounts. As allowed under the new accounting standard, the Company elected to apply practical expedients to carry forward the original lease determinations, leases classifications and accounting of initial direct costs for all asset classes at the time of adoption. The Company also elected not to separate lease components from non-lease components and to exclude short-term leases from its Consolidated Balance Sheet. The Company's adoption of the new standard resulted in the recognition of right-of-use assets of $458 and liabilities of $574, with no material cumulative effect adjustment to equity as of the date of adoption. In connection with the adoption of this guidance, as required, the Company reclassified certain restructuring reserves incurred in connection with the Global Growth and Efficiency Program (see Note 4, Restructuring and Related Implementation Charges to the Consolidated Financial Statements for additional information) and deferred rent liabilities as reductions to lease assets. Adoption of the new standard did not have a material impact on the Company's Consolidated Statements of Income or Cash Flows. See Note 15, Leases to the Consolidated Financial Statements for additional information.
(Dollars in Millions Except Per Share Amounts)
Outlook
Looking forward, we expect global macroeconomic, political and market conditions to remain challenging. Although we have seen improvement in category growth rates, we expect category growth rates to remain below historical levels. While the global marketplace in which we operate has always been highly competitive, we continue to experience heightened competitive activity in certain markets from strong local competitors, from other large multinational companies, some of which have greater resources than we do, and from new entrants into the market in many of our categories. Such activities have included more aggressive product claims and marketing challenges, as well as increased promotional spending and geographic expansion. We have also been negatively affected by changes in the policies or practices of our retail trade customers in key markets, such as inventory de-stocking, limitations on access to shelf space or delisting of our products. In addition, the retail landscape in many of our markets continues to be impacted by the rapid growth of eCommerce retailers, changing consumer preferences (as consumers increasingly shop online) and the emergence of alternative retail channels, such as subscription services and direct-to-consumer businesses. This rapid growth in eCommerce and the emergence of alternative retail channels have created and may continue to create pricing pressures and/or adversely affect our relationships with our key retailers. In addition, given that approximately 70% of our Net sales originate in markets outside the U.S., we have experienced and will likely continue to experience volatile foreign currency fluctuations and higher raw and packaging material costs. While we have taken, and will continue to take, measures to mitigate the effect of these conditions, should they persist, they could adversely affect our future results. In addition, although we are taking steps to mitigate the impact of the novel coronavirus on our business, we expect it will negatively impact our business and results of operations in the near term. Because this situation is continuing to develop, the full extent of the impact is not yet known and will depend on, among other things, the duration of quarantines and other travel restrictions, both within China and into and out of China, and the degree to which the virus spreads beyond currently affected geographies. For more information about factors that could impact our business see Part I, Item 1A "Risk Factors."
In summary, we believe we are well prepared to meet the challenges ahead due to our strong financial condition, experience operating in challenging environments and continued focus on our key priorities: growing sales through engaging with consumers, developing world-class innovation and working with retail partners; driving efficiency on every line of the income statement to increase margins; generating strong cash flow performance and utilizing that cash effectively to enhance total shareholder return; and leading to win by staying true to the Company’s culture and focusing on its stakeholders. Our commitment to these priorities, together with the strength of our global brands, our broad international presence in both developed and emerging markets and cost-saving initiatives, such as our funding-the-growth initiatives, should position us well to increase shareholder value over the long term.
(Dollars in Millions Except Per Share Amounts)
Results of Operations
This section of this Annual Report on Form 10-K generally discusses 2019 and 2018 items and year-to-year comparisons between 2019 and 2018. Discussions of 2017 items and year-to-year comparisons between 2018 and 2017 that are not included in this Annual Report on Form 10-K can be found in "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.
Net Sales
Worldwide Net sales were $15,693 in 2019, up 1.0% from 2018, as volume growth of 2.5% and net selling price increases of 2.0% were partially offset by negative foreign exchange of 3.5%. The Company’s acquisition of Filorga increased volume by 0.5%. Organic sales (Net sales excluding, as applicable, the impact of foreign exchange, acquisitions and divestments), a non-GAAP financial measure as discussed below, increased 4.0% in 2019.
Net sales in the Oral, Personal and Home Care product segment were $13,168 in 2019, even with 2018, as volume growth of 2.5% and net selling price increases of 1.5% were offset by negative foreign exchange of 4.0%. The Company’s acquisition of Filorga increased volume by 0.5%. Organic sales in the Oral, Personal and Home Care product segment increased 3.5% in 2019.
The increase in organic sales in 2019 versus 2018 was due to increases in Oral Care, Personal Care and Home Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste category. The increase in Personal Care was primarily due to organic sales growth in the skin health, body wash, bar soap, shampoo and underarm protection categories, partially offset by a decline in organic sales in the liquid hand soap category. The increase in Home Care was due to organic sales growth in the liquid cleaner and fabric softener categories.
The Company’s share of the global toothpaste market was 41.1% for full year 2019, down 0.7 share points from full year 2018, and its share of the global manual toothbrush market was 31.6% for full year 2019, down 0.5 share points from full year 2018. Full year 2019 market shares in toothpaste were flat in Europe and down in all other operating units versus full year 2018. In the manual toothbrush category, full year 2019 market shares were down in all operating units versus full year 2018. For additional information regarding the Company’s use of market share data and limitations of such data, see “Market Share Information” below.
Net sales for Hill’s Pet Nutrition were $2,525 in 2019, an increase of 6.0% from 2018, driven by volume growth of 3.5% and net selling price increases of 4.0%, partially offset by negative foreign exchange of 1.5%. Organic sales for Hill’s Pet Nutrition increased 7.5% in 2019.
The increase in organic sales in 2019 versus 2018 was primarily due to increases in organic sales in the Science Diet and Prescription Diet categories.
(Dollars in Millions Except Per Share Amounts)
Gross Profit/Margin
Worldwide Gross profit increased 1% to $9,325 in 2019 from $9,231 in 2018. Gross profit in both periods included charges resulting from the Global Growth and Efficiency Program. Excluding these charges in both periods and acquisition-related costs in 2019, Gross profit increased to $9,336 in 2019 from $9,262 in 2018, reflecting an increase of $90 resulting from higher Net sales, partially offset by a decrease of $16 resulting from lower Gross profit margin.
Worldwide Gross profit margin was 59.4% in 2019, even with 2018. Excluding charges resulting from the Global Growth and Efficiency Program in both periods and acquisition-related costs in 2019, Gross profit margin decreased by 10 basis points (bps) to 59.5% in 2019, from 59.6% in 2018. This decrease in Gross profit margin was primarily due to higher raw and packaging material costs (300 bps), which included foreign exchange transaction costs, largely offset by cost savings from the Company’s funding-the-growth initiatives (220 bps) and higher pricing (70 bps).
|
| | | | | | | | |
| | 2019 | | 2018 |
Gross profit, GAAP | | $ | 9,325 |
| | $ | 9,231 |
|
Global Growth and Efficiency Program | | 8 |
| | 31 |
|
Acquisition-related costs | | 3 |
| | — |
|
Gross profit, non-GAAP | | $ | 9,336 |
| | $ | 9,262 |
|
|
| | | | | | | | | |
| | 2019 | | 2018 | | Basis Point Change |
Gross profit margin, GAAP | | 59.4 | % | | 59.4 | % | | — |
|
Global Growth and Efficiency Program | | 0.1 |
| | 0.2 |
| | |
Acquisition-related costs | | — |
| | — |
| | |
Gross profit margin, non-GAAP | | 59.5 | % | | 59.6 | % | | (10 | ) |
(Dollars in Millions Except Per Share Amounts)
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased to $5,575 in 2019 from $5,389 in 2018. Selling, general and administrative expenses in both periods included charges resulting from the Global Growth and Efficiency Program. Excluding these charges in both periods, Selling, general and administrative expenses increased to $5,515 in 2019 from $5,356 in 2018, reflecting increased advertising investment of $104 and higher overhead expenses of $55.
Selling, general and administrative expenses as a percentage of Net sales increased to 35.5% in 2019 from 34.7% in 2018. Excluding charges resulting from the Global Growth and Efficiency Program in both periods, Selling, general and administrative expenses as a percentage of Net sales were 35.1% in 2019, an increase of 60 bps as compared to 2018. This increase in 2019 was due to increased advertising investment (60 bps) as a percentage of Net sales. In 2019, advertising investment increased as a percentage of Net sales to 10.8% from 10.2% in 2018 or 6.5% in absolute terms to $1,694 as compared with $1,590 in 2018.
|
| | | | | | | | |
| | 2019 | | 2018 |
Selling, general and administrative expenses, GAAP | | $ | 5,575 |
| | $ | 5,389 |
|
Global Growth and Efficiency Program | | (60 | ) | | (33 | ) |
Selling, general and administrative expenses, non-GAAP | | $ | 5,515 |
| | $ | 5,356 |
|
|
| | | | | | | | |
| | 2019 | | 2018 | | Basis Point Change |
Selling, general and administrative expenses as a percentage of Net sales, GAAP | | 35.5 | % | | 34.7 | % | | 80 |
Global Growth and Efficiency Program | | (0.4 | ) | | (0.2 | ) | | |
Selling, general and administrative expenses as a percentage of Net sales, non-GAAP | | 35.1 | % | | 34.5 | % | | 60 |
(Dollars in Millions Except Per Share Amounts)
Other (Income) Expense, Net
Other (income) expense, net was $196 and $148 in 2019 and 2018, respectively. Other (income) expense, net in both periods included charges related to the Global Growth and Efficiency Program. Other (income) expense, net in 2019 also included acquisition-related costs and the benefit related to a value-added tax matter in Brazil.
|
| | | | | | | | |
| | 2019 | | 2018 |
Other (income) expense, net, GAAP | | $ | 196 |
| | $ | 148 |
|
Global Growth and Efficiency Program | | (57 | ) | | (88 | ) |
Acquisition-related costs | | (21 | ) | | — |
|
Value-added tax matter in Brazil | | 30 |
| | — |
|
Other (income) expense, net, non-GAAP | | $ | 148 |
| | $ | 60 |
|
Excluding the items described above in both periods, as applicable, Other (income) expense, net was $148 in 2019 and $60 in 2018, comprised of the following:
|
| | | | | | | | |
| | 2019 | | 2018 |
Amortization of intangible assets | | 62 |
| | 59 |
|
Equity income | | (9 | ) | | (10 | ) |
Write-off of certain investments and fixed assets | | 51 |
| | 1 |
|
Charges for a change in go-to-market strategy in certain countries | | 15 |
| | — |
|
Other, net | | 29 |
| | 10 |
|
Total Other (income) expense, net | | $ | 148 |
| | $ | 60 |
|
(Dollars in Millions Except Per Share Amounts)
Operating Profit
Operating profit decreased 4% to $3,554 in 2019 from $3,694 in 2018.
In 2019 and 2018, Operating profit included charges resulting from the Global Growth and Efficiency Program. In 2019, Operating profit also included acquisition-related costs and a benefit related to a value-added tax matter in Brazil. Excluding these items in both periods, as applicable, Operating profit in 2019 decreased 4% compared to 2018, due to a decrease in Gross profit and increases in both Selling, general and administrative expenses and Other (income) expense.
Operating profit margin was 22.6% in 2019, a decrease of 120 bps compared with 23.8% in 2018. Excluding charges resulting from the Global Growth and Efficiency Program in both periods and acquisition-related costs and a benefit related to a value-added tax matter in Brazil in 2019, Operating profit margin decreased 130 bps to 23.4% in 2019 compared to 24.7% in 2018. This decrease in Operating profit in 2019 was due to a decrease in Gross profit (10 bps) and increases in Selling, general and administrative expenses (60 bps) and Other (income) expense, net (60 bps), all as a percentage of Net sales. |
| | | | | | | | | | | |
| | 2019 | | 2018 | | % Change |
Operating profit, GAAP | | $ | 3,554 |
| | $ | 3,694 |
| | (4 | )% |
Global Growth and Efficiency Program | | 125 |
| | 152 |
| | |
Acquisition-related costs | | 24 |
| | — |
| | |
Value-added tax matter in Brazil | | (30 | ) | | — |
| | |
Operating profit, non-GAAP | | $ | 3,673 |
| | $ | 3,846 |
| | (4 | )% |
|
| | | | | | | | | |
| | 2019 | | 2018 | | Basis Point Change |
Operating profit margin, GAAP | | 22.6 | % | | 23.8 | % | | (120 | ) |
Global Growth and Efficiency Program | | 0.8 |
| | 0.9 |
| | |
Acquisition-related costs | | 0.2 |
| | — |
| | |
Value-added tax matter in Brazil | | (0.2 | ) | | — |
| | |
Operating profit margin, non-GAAP | | 23.4 | % | | 24.7 | % | | (130 | ) |
Non-Service Related Postretirement Costs
Non-service related postretirement costs were $108 in 2019 compared to $87 in 2018. Non-service related postretirement costs in both periods included charges resulting from the Global Growth and Efficiency Program. Excluding these charges in both periods, Non-service related postretirement costs were $101 in 2019 compared to $78 in 2018. The increase in Non-service related postretirement costs in 2019 as compared to 2018 was primarily due to a lower expected return on plan assets and increased interest costs.
|
| | | | | | | | |
| | 2019 | | 2018 |
Non-service related postretirement costs, GAAP | | $ | 108 |
| | $ | 87 |
|
Global Growth and Efficiency Program | | (7 | ) | | (9 | ) |
Non-service related postretirement costs, non-GAAP | | $ | 101 |
| | $ | 78 |
|
Interest (Income) Expense, Net
Interest (income) expense, net was $145 in 2019 compared with $143 in 2018. The increase in Interest (income) expense, net in 2019 as compared to 2018 was primarily due to lower interest income on investments held outside the United States.
(Dollars in Millions Except Per Share Amounts)
Income Taxes
The effective income tax rate was 23.4% in 2019 and 26.2% in 2018. As reflected in the table below, the non-GAAP effective income tax rate was 24.1% in 2019 and 24.2% in 2018.
|
| | | | | | | | | | | |
| | 2019 |
| | Income Before Income Taxes | | Provision For Income Taxes(1) | | Effective Income Tax Rate(2) |
As Reported GAAP | | $ | 3,301 |
| | $ | 774 |
| | 23.4 | % |
Global Growth and Efficiency Program | | 132 |
| | 30 |
| | — |
|
Acquisition-related costs | | 24 |
| | 4 |
| | — |
|
Value-added tax matter in Brazil | | (30 | ) | | (10 | ) | | (0.1 | ) |
Swiss income tax reform | | — |
| | 29 |
| | 0.8 |
|
Non-GAAP | | $ | 3,427 |
| | $ | 827 |
| | 24.1 | % |
|
| | | | | | | | | | | |
| | 2018 |
| | Income Before Income Taxes | | Provision For Income Taxes(1) | | Effective Income Tax Rate(2) |
As Reported GAAP | | $ | 3,464 |
| | $ | 906 |
| | 26.2 | % |
Global Growth and Efficiency Program | | 161 |
| | 37 |
| | (0.1 | ) |
Benefit from a foreign tax matter | | — |
| | 15 |
| | 0.4 |
|
U.S. tax reform | | — |
| | (80 | ) | | (2.3 | ) |
Non-GAAP | | $ | 3,625 |
| | $ | 878 |
| | 24.2 | % |
_______
| |
(1) | The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. |
| |
(2) | The impact of non-GAAP items on the Company’s effective tax rate represents the difference in the effective tax rate calculated with and without the non-GAAP adjustment on Income before income taxes and Provision for income taxes. |
As a result of the enactment of the TCJA in the fourth quarter of 2017, the Company recorded a provisional charge of $275, based on its initial analysis of the TCJA using information and estimates available as of February 15, 2018, the date on which the Company filed its Annual Report on Form 10-K for the year ended December 31, 2017. During 2018, the Company finalized its assessment of the impact of the TCJA and recognized an additional tax expense of $80 reflecting the impact of transition tax guidance issued by the U.S. Treasury and the update of certain estimates and calculations based on information available through the end of 2018.
The effective income tax rate in all years benefited from tax planning associated with the Company’s global business initiatives.
(Dollars in Millions Except Per Share Amounts)
Net income attributable to Colgate-Palmolive Company and Earnings per share
Net income attributable to Colgate-Palmolive Company was $2,367, or $2.75 per share on a diluted basis, in 2019 compared to $2,400, or $2.75 per share on a diluted basis, in 2018. In 2019 and 2018, Net income attributable to Colgate-Palmolive Company included aftertax charges related to the Global Growth and Efficiency Program. In 2019, Net income attributable to Colgate-Palmolive Company also included aftertax acquisition-related costs, an aftertax benefit related to a value-added tax matter in Brazil and a tax benefit related to Swiss income tax reform. In 2018, Net income attributable to Colgate-Palmolive Company also included a benefit from a foreign tax matter and a charge related to U.S. tax reform. See "Income Taxes" above for additional information.
Excluding the items described above in both periods, as applicable, Net income attributable to Colgate-Palmolive Company decreased 6% to $2,440 in 2019 and Diluted earnings per share decreased 5% to $2.83, as compared to 2018. |
| | | | | | | | | | | | | | | | | | | | | | | |
| 2019 |
| Income Before Income Taxes | | Provision For Income Taxes(1) | | Net Income Including Noncontrolling Interests | | Less: Income Attributable To Noncontrolling Interests | | Net Income Attributable to Colgate-Palmolive Company | | Diluted Earnings Per Share(2) |
As Reported GAAP | $ | 3,301 |
| | $ | 774 |
| | $ | 2,527 |
| | $ | 160 |
| | $ | 2,367 |
| | $ | 2.75 |
|
Global Growth and Efficiency Program | 132 |
| | 30 |
| | 102 |
| | — |
| | 102 |
| | 0.12 |
|
Acquisition-related costs | 24 |
| | 4 |
| | 20 |
| | — |
| | 20 |
| | 0.02 |
|
Value-added tax matter in Brazil | (30 | ) | | (10 | ) | | (20 | ) | | — |
| | (20 | ) | | (0.02 | ) |
Swiss income tax reform | — |
| | 29 |
| | (29 | ) | | — |
| | (29 | ) | | (0.04 | ) |
Non-GAAP | $ | 3,427 |
| | $ | 827 |
| | $ | 2,600 |
| | $ | 160 |
| | $ | 2,440 |
| | $ | 2.83 |
|
|
| | | | | | | | | | | | | | | | | | | | | | | |
| 2018 |
| Income Before Income Taxes | | Provision For Income Taxes(1) | | Net Income Including Noncontrolling Interests | | Less: Income Attributable To Noncontrolling Interests | | Net Income Attributable to Colgate-Palmolive Company | | Diluted Earnings Per Share(2) |
As Reported GAAP | $ | 3,464 |
| | $ | 906 |
| | $ | 2,558 |
| | $ | 158 |
| | $ | 2,400 |
| | $ | 2.75 |
|
Global Growth and Efficiency Program | 161 |
| | 37 |
| | 124 |
| | (1 | ) | | 125 |
| | 0.15 |
|
Benefit from a foreign tax matter | — |
| | 15 |
| | (15 | ) | | — |
| | (15 | ) | | (0.02 | ) |
U.S. tax reform | — |
| | (80 | ) | | 80 |
| | — |
| | 80 |
| | 0.09 |
|
Non-GAAP | $ | 3,625 |
| | $ | 878 |
| | $ | 2,747 |
| | $ | 157 |
| | $ | 2,590 |
| | $ | 2.97 |
|
_______
| |
(1) | The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. |
| |
(2) | The impact of non-GAAP adjustments on diluted earnings per share may not necessarily equal the difference between “GAAP” and “non-GAAP” as a result of rounding. |
(Dollars in Millions Except Per Share Amounts)
Segment Results
The Company markets its products in over 200 countries and territories throughout the world in two product segments: Oral, Personal and Home Care; and Pet Nutrition. The Company evaluates segment performance based on several factors, including Operating profit. The Company uses Operating profit as a measure of the operating segment performance because it excludes the impact of corporate-driven decisions related to interest expense and income taxes.
Oral, Personal and Home Care
North America
|
| | | | | | | | | | | |
| 2019 | | 2018 | | % Change |
Net sales | $ | 3,424 |
| | $ | 3,348 |
| | 2.0 |
| % |
Operating profit | $ | 982 |
| | $ | 1,037 |
| | (5 | ) | % |
% of Net sales | 28.7 | % | | 31.0 | % | | (230 | ) | bps |
Net sales in North America increased 2.0% in 2019 to $3,424, as volume growth of 2.0% and net selling price increases of 0.5% were partially offset by negative foreign exchange of 0.5%. Organic sales in North America increased 2.5% in 2019.
The increase in organic sales in North America in 2019 versus 2018 was due to increases in Oral Care, Personal Care and Home Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste category, partially offset by declines in organic sales in the manual toothbrush and mouthwash categories. The increase in Personal Care was primarily due to organic sales growth in the skin health, body wash and bar soap categories, partially offset by a decline in organic sales in the liquid hand soap category. The increase in Home Care was primarily due to organic sales growth in the liquid cleaner and fabric softener categories, partially offset by a decline in organic sales in the hand dish category.
Operating profit in North America decreased 5% in 2019 to $982, or 230 bps to 28.7% of Net sales. This decrease in Operating profit as a percentage of Net sales was due to a decrease in Gross profit (130 bps), an increase in Selling, general and administrative expenses (70 bps) and an increase in Other (income) expense, net (30 bps), all as a percentage of Net sales. This decrease in Gross profit was primarily due to higher raw and packaging material costs (300 bps), partially offset by cost savings from the Company’s funding-the-growth initiatives (210 bps). This increase in Selling, general and administrative expenses was due to increased advertising investment (50 bps) and higher overhead expenses (20 bps). This increase in Other (income) expense, net was primarily due to the write-off of certain fixed assets.
(Dollars in Millions Except Per Share Amounts)
Latin America
|
| | | | | | | | | | | |
| 2019 | | 2018 | | % Change |
Net sales | $ | 3,606 |
| | $ | 3,605 |
| | — |
| % |
Operating profit | $ | 963 |
| | $ | 995 |
| | (3 | ) | % |
% of Net sales | 26.7 | % | | 27.6 | % | | (90 | ) | bps |
Net sales in Latin America were $3,606 in 2019, even with 2018, as volume growth of 3.0% and net selling price increases of 4.0% were offset by negative foreign exchange of 7.0%. Volume gains were led by Mexico, Brazil and Central America. Organic sales in Latin America increased 7.0% in 2019.
The increase in organic sales in Latin America in 2019 versus 2018 was due to increases in Oral Care, Personal Care and Home Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste and manual toothbrush categories. The increase in Personal Care was primarily due to organic sales growth in the bar soap and shampoo categories. The increase in Home Care was primarily due to organic sales growth in the liquid cleaner, fabric softener and hand dish categories.
Operating profit in Latin America decreased 3% in 2019 to $963, or 90 bps to 26.7% of Net sales. This decrease in Operating profit as a percentage of Net sales was primarily due to an increase in Selling, general and administrative expenses (80 bps), partially offset by an increase in Gross profit (10 bps), both as a percentage of Net sales. This increase in Gross profit was primarily due to cost savings from the Company’s funding-the-growth initiatives (240 bps) and higher pricing, which were partially offset by higher raw and packaging material costs (360 bps), which included foreign exchange transaction costs. This increase in Selling, general and administrative expenses was due to higher overhead expenses (70 bps) and increased advertising investment (10 bps).
(Dollars in Millions Except Per Share Amounts)
Europe
|
| | | | | | | | | | | |
| 2019 | | 2018 | | % Change |
Net sales | $ | 2,450 |
| | $ | 2,502 |
| | (2.0 | ) | % |
Operating profit | $ | 624 |
| | $ | 634 |
| | (2 | ) | % |
% of Net sales | 25.5 | % | | 25.3 | % | | 20 |
| bps |
Net sales in Europe decreased 2.0% in 2019 to $2,450, as volume growth of 4.0% was more than offset by net selling price decreases of 0.5% and negative foreign exchange of 5.5%. Volume gains were led by France, Spain and the United Kingdom. The Filorga acquisition, which closed on September 19, 2019, contributed 3.0% to volume in Europe. Organic sales in Europe increased 0.5% in 2019.
The increase in organic sales in Europe in 2019 versus 2018 was primarily due to an increase in Oral Care organic sales, partially offset by a decline in Personal Care organic sales. The increase in Oral Care was driven by organic sales growth in the toothpaste category, partially offset by a decline in organic sales in the battery-powered toothbrush category. The decrease in Personal Care was primarily due to declines in organic sales in the liquid hand soap and shampoo categories.
Operating profit in Europe decreased 2% in 2019 to $624, while as a percentage of Net sales it increased 20 bps to 25.5%. This increase in Operating profit as a percentage of Net sales was primarily due to an increase in Gross profit (80 bps), partially offset by an increase in Selling, general and administrative expenses (50 bps), both as a percentage of Net sales. This increase in Gross profit was primarily due to cost savings from the Company’s funding-the-growth initiatives (170 bps) and mix (80 bps) primarily due to the Company's acquisition of Filorga, partially offset by higher raw and packaging material costs (140 bps). This increase in Selling, general and administrative expenses was due to higher overhead expenses (30 bps) and increased advertising investment (20 bps).
(Dollars in Millions Except Per Share Amounts)
Asia Pacific
|
| | | | | | | | | | | |
| 2019 | | 2018 | | % Change |
Net sales | $ | 2,707 |
| | $ | 2,734 |
| | (1.0 | ) | % |
Operating profit | $ | 749 |
| | $ | 777 |
| | (4 | ) | % |
% of Net sales | 27.7 | % | | 28.4 | % | | (70 | ) | bps |
Net sales in Asia Pacific decreased 1.0% in 2019 to $2,707, as volume growth of 0.5% and net selling price increases of 1.0% were more than offset by negative foreign exchange of 2.5%. Volume gains were led by the Philippines, Australia and Thailand. Organic sales in Asia Pacific increased 1.5% in 2019.
The increase in organic sales in 2019 versus 2018 was primarily due to an increase in Oral Care organic sales. The increase in Oral Care was driven by organic sales growth in the toothpaste category, partially offset by a decline in organic sales in the manual toothbrush category.
Operating profit in Asia Pacific decreased 4% in 2019 to $749, or 70 bps to 27.7% of Net sales. This decrease in Operating profit as a percentage of Net sales was primarily due to a decrease in Gross profit (10 bps) and an increase in Selling, general and administrative expenses (70 bps), both as a percentage of Net sales. This decrease in Gross profit was primarily due to higher raw and packaging material costs (310 bps), largely offset by cost savings from the Company’s funding-the-growth initiatives (270 bps) and higher pricing. This increase in Selling, general and administrative expenses was due to increased advertising investment (80 bps), partially offset by lower overhead expenses (10 bps).
(Dollars in Millions Except Per Share Amounts)
Africa/Eurasia
|
| | | | | | | | | | | |
| 2019 | | 2018 | | % Change |
Net sales | $ | 981 |
| | $ | 967 |
| | 1.5 |
| % |
Operating profit | $ | 187 |
| | $ | 173 |
| | 8 |
| % |
% of Net sales | 19.1 | % | | 17.9 | % | | 120 |
| bps |
Net sales in Africa/Eurasia increased 1.5% in 2019 to $981, as volume growth of 3.5% and net selling price increases of 4.0% were partially offset by negative foreign exchange of 6.0%. Volume gains were led by Russia, Kenya and the Gulf States. The Company’s acquisition of a 51% controlling interest in Colgate Toloram Pte. Ltd., a joint venture which owns the Nigeria-based Hypo Homecare Products Limited (the "Nigeria Joint Venture"), contributed 0.5% to volume in Africa/Eurasia. Organic sales in Africa/Eurasia increased 7.0% in 2019.
The increase in organic sales in 2019 versus 2018 was primarily due to an increase in Oral Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste and manual toothbrush categories.
Operating profit in Africa/Eurasia increased 8% in 2019 to $187, or 120 bps to 19.1% of Net sales. This increase in Operating profit as a percentage of Net sales was primarily due to an increase in Gross Profit (170 bps), partially offset by an increase in Selling, general and administrative expenses (50 bps), both as a percentage of Net sales. This increase in Gross profit was mainly driven by cost savings from the Company’s funding-the-growth initiatives (290 bps) and higher pricing, partially offset by higher raw and packaging material costs (380 bps), which included foreign exchange transaction costs. The increase in Selling, general and administrative expenses was due to increased advertising investment (130 bps), partially offset by lower overhead expenses (80 bps).
(Dollars in Millions Except Per Share Amounts)
Hill’s Pet Nutrition
|
| | | | | | | | | | | |
| 2019 | | 2018 | | % Change |
Net sales | $ | 2,525 |
| | $ | 2,388 |
| | 6.0 |
| % |
Operating profit | $ | 703 |
| | $ | 680 |
| | 3 |
| % |
% of Net sales | 27.8 | % | | 28.5 | % | | (70 | ) | bps |
Net sales for Hill’s Pet Nutrition increased 6.0% in 2019 to $2,525, as volume growth of 3.5% and net selling price increases of 4.0% were partially offset by negative foreign exchange of 1.5%. Volume gains were led by the United States, Western Europe and Australia. Organic sales in Hill’s Pet Nutrition increased 7.5% in 2019.
The increase in organic sales in 2019 versus 2018 was due to organic sales growth in the Science Diet and Prescription Diet categories.
Operating profit in Hill’s Pet Nutrition increased to $703 in 2019 from $680 in 2018, while as a percentage of Net sales it decreased 70 bps to 27.8%. This decrease in Operating profit as a percentage of Net sales was due to a decrease in Gross profit (40 bps) and an increase in Selling, general and administrative expenses (30 bps), both as a percentage of Net sales. This decrease in Gross profit was primarily due to higher raw and packaging material costs (300 bps), partially offset by cost savings from the Company’s funding-the-growth initiatives (160 bps) and higher pricing. This increase in Selling, general and administrative expenses was due to increased advertising investment (140 bps), partially offset by lower overhead expenses (110 bps).
During the quarter ended March 31, 2019, Hill’s announced a voluntary recall, which was subsequently expanded, of select canned dog food products due to potentially elevated levels of Vitamin D resulting from a supplier error. In the United States, the voluntary recall was conducted in cooperation with the U.S. Food and Drug Administration. Following the announcement of the voluntary recall, and as of December 31, 2019, Hill’s and/or the Company have been named as defendants in 37 putative class action lawsuits, one putative class action filed on behalf of a European Union class and one individual action, all related to the voluntary recall and filed in various jurisdictions in the United States. In addition, two putative class actions related to the voluntary recall have been filed in Canada. Eight of the putative class actions lawsuits in the United States have been voluntarily dismissed. Hill’s is entitled to indemnification from the supplier related to the voluntary recall. Sales of products voluntarily recalled represent less than 2% of Hill’s annual Net sales. The sales loss and other costs associated with the voluntary recall and subsequent expansion did not have a material impact on the Company’s Net sales or Operating profit for the year ended December 31, 2019 and are not expected to have a material impact in future periods.
(Dollars in Millions Except Per Share Amounts)
Corporate
|
| | | | | | | | | | |
| 2019 | | 2018 | | % Change |
Operating profit (loss) | $ | (654 | ) | | $ | (602 | ) | | |